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Summary
The health-care facility environment is rarely implicated in disease transmission, except among patients who are
immunocompromised. Nonetheless, inadvertent exposures to environmental pathogens (e.g., Aspergillus spp. and Legionella
spp.) or airborne pathogens (e.g., Mycobacterium tuberculosis and varicella-zoster virus) can result in adverse patient outcomes
and cause illness among health-care workers. Environmental infection-control strategies and engineering controls can effectively
prevent these infections. The incidence of health-care–associated infections and pseudo-outbreaks can be minimized by 1) appro-
priate use of cleaners and disinfectants; 2) appropriate maintenance of medical equipment (e.g., automated endoscope reprocessors
or hydrotherapy equipment); 3) adherence to water-quality standards for hemodialysis, and to ventilation standards for special-
ized care environments (e.g., airborne infection isolation rooms, protective environments, or operating rooms); and 4) prompt
management of water intrusion into the facility. Routine environmental sampling is not usually advised, except for water quality
determinations in hemodialysis settings and other situations where sampling is directed by epidemiologic principles, and results can
be applied directly to infection-control decisions.
This report reviews previous guidelines and strategies for preventing environment-associated infections in health-care facilities
and offers recommendations. These include 1) evidence-based recommendations supported by studies; 2) requirements of federal
agencies (e.g., Food and Drug Administration, U.S. Environmental Protection Agency, U.S. Department of Labor, Occupational
Safety and Health Administration, and U.S. Department of Justice); 3) guidelines and standards from building and equipment
professional organizations (e.g., American Institute of Architects, Association for the Advancement of Medical Instrumentation,
and American Society of Heating, Refrigeration, and Air-Conditioning Engineers); 4) recommendations derived from scientific
theory or rationale; and 5) experienced opinions based upon infection-control and engineering practices. The report also suggests a
series of performance measurements as a means to evaluate infection-control efforts.
Introduction
Parameters of the Report
This report, which contains the complete list of recommen-
dations with pertinent references, is Part II of Guidelines for
Environmental Infection Control in Health-Care Facilities. The
full four-part guidelines will be available on CDC’s Division
of Healthcare Quality Promotion (DHQP) website. Relative
to previous CDC guidelines, this report
• revises multiple sections (e.g., cleaning and disinfection
of environmental surfaces, environmental sampling, laun-
dry and bedding, and regulated medical waste) from pre-
vious editions of CDC’s Guideline for Handwashing and
Hospital Environmental Control;
• incorporates discussions of air and water environmental
concerns from CDC’s Guideline for Prevention of Nosoco-
mial Pneumonia;
• consolidates relevant environmental infection-control
measures from other CDC guidelines; and
• includes two topics not addressed in previous CDC guide-
lines — infection-control concerns related to animals in
health-care facilities and water quality in hemodialysis
settings.
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In the full guidelines, Part I, Background Information:
Environmental Infection Control in Health-Care Facilities,
provides a comprehensive review of the relevant scientific lit-
erature. Attention is given to engineering and infection-
control concerns during construction, demolition, renovation,
and repair of health-care facilities. Use of an infection-control
risk assessment is strongly supported before the start of these
or any other activities expected to generate dust or water aero-
sols. Also reviewed in Part I are infection-control measures
used to recover from catastrophic events (e.g., flooding, sew-
age spills, loss of electricity and ventilation, or disruption of
water supply) and the limited effects of environmental sur-
faces, laundry, plants, animals, medical wastes, cloth furnish-
ings, and carpeting on disease transmission in health-care
facilities. Part III and Part IV of the full guidelines provide
references (for the complete guideline) and appendices, respec-
tively.
Part II (this report) contains recommendations for environ-
mental infection control in health-care facilities, describing
control measures for preventing infections associated with air,
water, or other elements of the environment. These recom-
mendations represent the views of different divisions within
CDC’s National Center for Infectious Diseases and the
Healthcare Infection Control Practices Advisory Committee
(HICPAC), a 12-member group that advises CDC on con-
cerns related to the surveillance, prevention, and control of
health-care–associated infections, primarily in U.S. health-care
facilities. In 1999, HICPAC’s infection-control focus was
expanded from acute-care hospitals to all venues where health
care is provided (e.g., outpatient surgical centers, urgent care
centers, clinics, outpatient dialysis centers, physicians’ offices,
and skilled nursing facilities). The topics addressed in this
report are applicable to the majority of health-care facilities in
the United States. This report is intended for use primarily by
infection-control practitioners, epidemiologists, employee
health and safety personnel, engineers, facility managers,
information systems professionals, administrators, environ-
mental service professionals, and architects. Key recommen-
dations include
• infection-control impact of ventilation system and water
system performance;
• establishment of a multidisciplinary team to conduct
infection-control risk assessment;
• use of dust-control procedures and barriers during con-
struction, repair, renovation, or demolition;
• environmental infection-control measures for special
areas with patients at high risk;
• use of airborne-particle sampling to monitor the effec-
tiveness of air filtration and dust-control measures;
• procedures to prevent airborne contamination in operat-
ing rooms when infectious tuberculosis (TB) patients
require surgery;
• guidance regarding appropriate indications for routine
culturing of water as part of a comprehensive control pro-
gram for legionellae;
• guidance for recovering from water-system disruptions,
water leaks, and natural disasters (e.g., flooding);
• infection-control concepts for equipment using water from
main lines (e.g., water systems for hemodialysis, ice
machines, hydrotherapy equipment, dental unit water
lines, and automated endoscope reprocessors);
• environmental surface cleaning and disinfection strategies
with respect to antibiotic-resistant microorganisms;
• infection-control procedures for health-care laundry;
• use of animals in health care for activities and therapy;
• managing the presence of service animals in health-care
facilities;
• infection-control strategies for when animals receive treat-
ment in human health-care facilities; and
• a call to reinstate the practice of inactivating amplified
cultures and stocks of microorganisms onsite during medi-
cal waste treatment.
Topics outside the scope of this report include 1) noninfec-
tious adverse events (e.g., sick building syndrome), 2) envi-
ronmental concerns in the home, 3) home health care, 4)
terrorism, and 5) health-care–associated foodborne illness.
Wherever possible, the recommendations in this report are
based on data from well-designed scientific studies. However,
certain of these studies were conducted by using narrowly
defined patient populations or specific health-care settings (e.g.,
hospitals versus long-term care facilities), making generaliza-
tion of findings potentially problematic. Construction stan-
dards for hospitals or other health-care facilities may not apply
to residential home-care units. Similarly, infection-control
measures indicated for immunosuppressed patient care are
usually not necessary in those facilities where such patients are
not present.
Other recommendations were derived from knowledge
gained during infectious disease investigations in health-care
facilities, where successful termination of the outbreak was
often the result of multiple interventions, the majority of which
cannot be independently and rigorously evaluated. This is
especially true for construction situations involving air or
water.
Other recommendations were derived from empiric engi-
neering concepts and may reflect industry standards rather
than evidence-based conclusions. Where recommendations
refer to guidance from the American Institute of Architects
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(AIA), the statements reflect standards intended for new con-
struction or renovation. Existing structures and engineered
systems are expected to be in continued compliance with those
standards in effect at the time of construction or renovation.
Also, in the absence of scientific confirmation, certain
infection-control recommendations that cannot be rigorously
evaluated are based on strong theoretic rationale and sugges-
tive evidence. Finally, certain recommendations are derived
from existing federal regulations.
Performance Measurements
Infections caused by the microorganisms described in this
guideline are rare events, and the effect of these recommenda-
tions on infection rates in a facility may not be readily mea-
surable. Therefore, the following steps to measure performance
are suggested to evaluate these recommendations:
1. Document whether infection-control personnel are
actively involved in all phases of a health-care facility’s
demolition, construction, and renovation. Activities
should include performing a risk assessment of the nec-
essary types of construction barriers, and daily monitor-
ing and documenting of the presence of negative airflow
within the construction zone or renovation area.
2. Monitor and document daily the negative airflow in AII
rooms and positive airflow in PE rooms, especially when
patients are in these rooms.
3. Perform assays at least once a month by using standard
quantitative methods for endotoxin in water used to
reprocess hemodialyzers, and for heterotrophic and
mesophilic bacteria in water used to prepare dialysate
and for hemodialyzer reprocessing.
4. Evaluate possible environmental sources (e.g., water,
laboratory solutions, or reagents) of specimen contami-
nation when nontuberculous mycobacteria (NTM) of
unlikely clinical importance are isolated from clinical
cultures. If environmental contamination is found, elimi-
nate the probable mechanisms.
5. Document policies to identify and respond to water dam-
age. Such policies should result in either repair and dry-
ing of wet structural or porous materials within 72 hours,
or removal of the wet material if drying is unlikely within
72 hours.
Updates to Previous Recommendations
Contributors to this report reviewed primarily English-
language manuscripts identified from reference searches using
the National Library of Medicine’s MEDLINE, bibliographies
of published articles, and infection-control textbooks. All the
recommendations may not reflect the opinions of all review-
ers. This report updates the following published guidelines
and recommendations:
CDC. Guideline for handwashing and hospital environmen-
tal control. MMWR 1998;37(No. 24). Replaces sections on
microbiologic sampling, laundry, infective waste, and house-
keeping.
Tablan OC, Anderson LJ, Arden NH, et al., Hospital Infec-
tion Control Practices Advisory Committee. Guideline for pre-
vention of nosocomial pneumonia. Infect Control Hosp
Epidemiol 1994;15:587–627. Updates and expands environ-
mental infection-control information for aspergillosis and
Legionnaires disease; online version incorporates Appendices B,
C, and D addressing environmental control and detection of
Legionella spp.
CDC. Guidelines for preventing the transmission of myco-
bacterium tuberculosis in health-care facilities. MMWR
1994;43(No. RR13). Provides supplemental information on
engineering controls.
CDC. Recommendations for preventing the spread of van-
comycin resistance: recommendations of the Hospital Infec-
tion Control Practices Advisory Committee (HICPAC).
MMWR 1995;44(No. RR12). Supplements environmental
infection-control information from the section, Hospitals with
Endemic VRE or Continued VRE Transmission.
Garner JS, Hospital Infection Control Practices Advisory
Committee. Guideline for isolation precautions in hospitals.
Infect Control Hosp Epidemiol 1996;17:53–80. Supplements
and updates topics in Part II — Recommendations for Isola-
tion Precautions in Hospitals (linen and laundry, routine and
terminal cleaning, airborne precautions).
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR,
Hospital Infection Control Practices Advisory Committee.
Guideline for prevention of surgical site infection. Infect Con-
trol Hosp Epidemiol 1999;4:250–78. Updates operating room
ventilation and surface cleaning/disinfection recommendations
from the section, Intraoperative Issues: Operating Room
Environment.
U.S. Public Health Service, Infectious Diseases Society
of America, Prevention of Opportunistic Infections Working
Group. USPHS/IDSA guidelines for the prevention of
opportunistic infections in persons infected with human
immunodeficiency virus. Infect Dis Obstet Gynecol 2002;
10:3–64. Supplements information regarding patient interac-
tion with pets and animals in the home.
CDC, Infectious Diseases Society of America, American
Society of Blood and Marrow Transplantation. Guidelines for
preventing opportunistic infections among hematopoietic stem
cell transplant recipients. Cytotherapy 2001;3:41–54. Supple-
ments and updates the section, Hospital Infection Control.
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Key Terms
Airborne infection isolation (AII) refers to the isolation of
patients infected with organisms spread via airborne droplet
nuclei <5 µm in diameter. This isolation area receives numer-
ous air changes per hour (ACH) (>12 ACH for new construc-
tion as of 2001; >6 ACH for construction before 2001), and
is under negative pressure, such that the direction of the air
flow is from the outside adjacent space (e.g., the corridor) into
the room. The air in an AII room is preferably exhausted to
the outside, but may be recirculated provided that the return
air is filtered through a high-efficiency particulate air (HEPA)
filter. The use of personal respiratory protection is also indi-
cated for persons entering these rooms when caring for TB or
smallpox patients and for staff who lack immunity to airborne
viral diseases (e.g., measles or varicella zoster virus [VZV]
infection).
Protective environment (PE) is a specialized patient-care
area, usually in a hospital, with a positive air flow relative to
the corridor (i.e., air flows from the room to the outside adja-
cent space). The combination of HEPA filtration, high num-
bers of air changes per hour (>12 ACH), and minimal leakage
of air into the room creates an environment that can safely
accommodate patients who have undergone allogeneic hemato-
poietic stem cell transplant (HSCT).
Immunocompromised patients are those patients whose
immune mechanisms are deficient because of immunologic
disorders (e.g., human immunodeficiency virus [HIV] infec-
tion or congenital immune deficiency syndrome), chronic dis-
eases (e.g., diabetes, cancer, emphysema, or cardiac failure), or
immunosuppressive therapy (e.g., radiation, cytotoxic chemo-
therapy, anti-rejection medication, or steroids). Immuno-
compromised patients who are identified as high-risk patients
have the greatest risk of infection caused by airborne or water-
borne microorganisms. Patients in this subset include persons
who are severely neutropenic for prolonged periods of time
(i.e., an absolute neutrophil count [ANC] of <500 cells/mL),
allogeneic HSCT patients, and those who have received the
most intensive chemotherapy (e.g., childhood acute myelog-
enous leukemia patients).
Abbreviations
AAMI Association for the Advancement of Medical
Instrumentation
ACH air changes per hour
AER automated endoscope reprocessor
AHJ authority having jurisdiction
AIA American Institute of Architects
AII airborne infection isolation
ANSI American National Standards Institute
ASHRAE American Society of Heating, Refrigeration, and
Air-Conditioning Engineers
BMBL Biosafety in Microbiological and Biomedical
Laboratories (CDC/National Institutes of
Health)
CFR Code of Federal Regulations
CJD Creutzfeldt-Jakob disease
CPL compliance document (OSHA)
DFA direct fluorescence assay
DHHS U.S. Department of Health and Human Services
DOT U.S. Department of Transportation
EC environment of care
EPA U. S. Environmental Protection Agency
FDA U.S. Food and Drug Administration
HBV hepatitis B virus
HEPA high efficiency particulate air
HIV human immunodeficiency virus
HSCT hematopoietic stem cell transplant
HVAC heating, ventilation, air conditioning
ICRA infection-control risk assessment
JCAHO Joint Commission on Accreditation of
Healthcare Organizations
NaOH sodium hydroxide
NTM nontuberculous mycobacteria
OSHA Occupational Safety and Health Administration
PE protective environment
PPE personal protective equipment
TB tuberculosis
USC United States Code
USDA U.S. Department of Agriculture
UV ultraviolet
UVGI ultraviolet germicidal irradiation
VHF viral hemorrhagic fever
VRE vancomycin-resistant Enterococcus
VRSA vancomycin-resistant Staphylococcus aureus
VZV varicella zoster virus
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Recommendations
for Environmental Infection
Control in Health-Care Facilities
Rationale for Recommendations
As in previous CDC guidelines, each recommendation is
categorized on the basis of existing scientific data, theoretic
rationale, applicability, and possible economic effect. The rec-
ommendations are evidence-based wherever possible. How-
ever, certain recommendations are derived from empiric
infection-control or engineering principles, theoretic rationale,
or from experience gained from events that cannot be readily
studied (e.g., floods).
The HICPAC system for categorizing recommendations has
been modified to include a category for engineering standards
and actions required by state or federal regulations. Guide-
lines and standards published by the AIA, American Society
of Heating, Refrigeration, and Air-Conditioning Engineers
(ASHRAE), and the Association for the Advancement of
Medical Instrumentation (AAMI) form the basis of certain
recommendations. These standards reflect a consensus of
expert opinions and extensive consultation with agencies of
the U.S. Department of Health and Human Services. Com-
pliance with these standards is usually voluntary. However,
state and federal governments often adopt these standards as
regulations. For example, the standards from AIA regarding
construction and design of new or renovated health-care
facilities, have been adopted by reference by >40 states. Cer-
tain recommendations have two category ratings (e.g., Cat-
egories IA and IC or Categories IB and IC), indicating the
recommendation is evidence-based as well as a standard or
regulation.
Rating Categories
Recommendations are rated according to the following cat-
egories:
Category IA. Strongly recommended for implementation
and strongly supported by well-designed experimental, clini-
cal, or epidemiologic studies.
Category IB. Strongly recommended for implementation
and supported by certain experimental, clinical, or epidemio-
logic studies and a strong theoretic rationale.
Category IC. Required by state or federal regulation, or
representing an established association standard. (Note: Ab-
breviations for governing agencies and regulatory citations are
listed where appropriate. Recommendations from regulations
adopted at state levels are also noted. Recommendations from
AIA guidelines cite the appropriate sections of the standards.)
Category II. Suggested for implementation and supported
by suggestive clinical or epidemiologic studies, or a theoretic
rationale.
Unresolved issue. No recommendation is offered. No con-
sensus or insufficient evidence exists regarding efficacy.
Recommendations — Air
I. Air-Handling Systems in Health-Care Facilities
A. Use AIA guidelines as minimum standards where
state or local regulations are not in place for design
and construction of ventilation systems in new or
renovated health-care facilities. Ensure that existing
structures continue to meet the specifications in
effect at the time of construction (1). Category IC
(AIA: 1.1.A, 5.4)
B. Monitor ventilation systems in accordance with
engineers’ and manufacturers’ recommendations to
ensure preventive engineering, optimal performance
for removal of particulates, and elimination of
excess moisture (1–8). Category IB, IC (AIA: 7.2,
7.31.D, 8.31.D, 9.31.D, 10.31.D, 11.31.D, Envi-
ronmental Protection Agency [EPA] guidance)
1. Ensure that heating, ventilation, air
conditioning (HVAC) filters are properly
installed and maintained to prevent air
leakages and dust overloads (2,4,6,9).
Category IB
2. Monitor areas with special ventilation
requirements (e.g., AII or PE) for ACH,
filtration, and pressure differentials (1,7,8,10–
26). Category IB, IC (AIA: 7.2.C7, 7.2.D6)
a. Develop and implement a maintenance
schedule for ACH, pressure differentials, and
filtration efficiencies by using facility-specific
data as part of the multidisciplinary risk
assessment. Take into account the age and
reliability of the system.
b. Document these parameters, especially the
pressure differentials.
3. Engineer humidity controls into the HVAC sys-
tem and monitor the controls to ensure adequate
moisture removal (1). Category IC (AIA:
7.31.D9)
a. Locate duct humidifiers upstream from the
final filters.
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b. Incorporate a water-removal mechanism into
the system.
c. Locate all duct takeoffs sufficiently down-
stream from the humidifier so that moisture
is completely absorbed.
4. Incorporate steam humidifiers, if possible, to
reduce potential for microbial proliferation
within the system, and avoid use of cool-mist
humidifiers. Category II
5. Ensure that air intakes and exhaust outlets are
located properly in construction of new facili-
ties and renovation of existing facilities (1,27).
Category IC (AIA: 7.31.D3, 8.31.D3, 9.31.D3,
10.31.D3, 11.31.D3)
a. Locate exhaust outlets >25 ft from air-
intake systems.
b. Locate outdoor air intakes >6 ft above
ground or >3 ft above roof level.
c. Locate exhaust outlets from contaminated
areas above roof level to minimize recircula-
tion of exhausted air.
6. Maintain air intakes and inspect filters periodi-
cally to ensure proper operation (1,11–16,27).
Category IC (AIA: 7.31.D8)
7. Bag dust-filled filters immediately upon removal
to prevent dispersion of dust and fungal spores
during transport within the facility (4,28). Cat-
egory IB
a. Seal or close the bag containing the discarded
filter.
b. Discard spent filters as regular solid waste,
regardless of the area from which they were
removed (28).
8. Remove bird roosts and nests near air intakes to
prevent mites and fungal spores from entering
the ventilation system (27,29,30). Category IB
9. Prevent dust accumulation by cleaning air-duct
grilles in accordance with facility-specific pro-
cedures and schedules and when rooms are not
occupied by patients (1,10–16). Category IC,
II (AIA: 7.31.D10)
10. Periodically measure output to monitor system
function; clean ventilation ducts as part of rou-
tine HVAC maintenance to ensure optimum
performance (1,31,32). Category IC, II (AIA:
7.31.D10)
C. Use portable, industrial-grade HEPA filter units
capable of filtration rates in the range of 300–800
ft3/min to augment removal of respirable particles
as needed (33). Category II
1. Select portable HEPA filters that can recirculate
all or nearly all of the room air and provide the
equivalent of >12 ACH (34). Category II
2. Portable HEPA filter units placed in construc-
tion zones can be used later in patient-care ar-
eas, provided all internal and external surfaces
are cleaned, and the filter replaced or its perfor-
mance verified by appropriate particle testing.
Category II
3. Situate portable HEPA units with the advice of
facility engineers to ensure that all room air is
filtered (34). Category II
4. Ensure that fresh-air requirements for the area
are met (33,35). Category II
D. Follow appropriate procedures for use of areas with
through-the-wall ventilation units (1). Category IC
(AIA: 8.31.D1, 8.31.D8, 9.31.D23, 10.31.D18,
11.31.D15)
1. Do not use such areas as PE rooms (1). Cat-
egory IC (AIA: 7.2.D3)
2. Do not use a room with a through-the-wall ven-
tilation unit as an AII room unless it can be dem-
onstrated that all required AII engineering
controls are met (1,34). Category IC (AIA:
7.2.C3)
E. Conduct an infection-control risk assessment
(ICRA) and provide an adequate number of AII and
PE rooms (if required) or other areas to meet the
needs of the patient population (1,2,7,8,17,19,
20,34,36–43). Category IA, IC (AIA: 7.2.C, 7.2.D)
F. When ultraviolet germicidal irradiation (UVGI) is
used as a supplemental engineering control, install
fixtures 1) on the wall near the ceiling or suspended
from the ceiling as an upper air unit; 2) in the air-
return duct of an AII area; or 3) in designated
enclosed areas or booths for sputum induction (34).
Category II
G. Seal windows in buildings with centralized HVAC
systems, including PE areas (1,3,44). Category IB,
IC (AIA: 7.2.D3)
H. Keep emergency doors and exits from PE rooms
closed except during an emergency; equip emergency
doors and exits with alarms. Category II
I. Develop a contingency plan for backup capacity in
the event of a general power failure (45). Category
IC (Joint Commission on Accreditation of
Healthcare Organizations [JCAHO]: Environment
of Care [EC] 1.4)
1. Emphasize restoration of appropriate air qual-
ity and ventilation conditions in AII rooms, PE
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rooms, operating rooms, emergency depart-
ments, and intensive care units (1,45). Category
IC (AIA: 1.5.A1; JCAHO: EC 1.4)
2. Deploy infection-control procedures to protect
occupants until power and systems functions are
restored (1,36,45). Category IC (AIA: 5.1, 5.2;
JCAHO: EC 1.4)
J. Do not shut down HVAC systems in patient-care
areas exept for maintenance, repair, testing of emer-
gency backup capacity, or new construction (1,46).
Category IB, IC (AIA: 5.1, 5.2.B, C)
1. Coordinate HVAC system maintenance with
infection-control staff and relocate immuno-
compromised patients if necessary (1). Category
IC (AIA: 5.1, 5.2)
2. Provide backup emergency power and air-
handling and pressurization systems to main-
tain filtration, constant ACH, and pressure dif-
ferentials in PE rooms, AII rooms, operating
rooms, and other critical-care areas (1,37,47).
Category IC (AIA: 5.1, 5.2)
3. For areas not served by installed emergency ven-
tilation and backup systems, use portable units
and monitor ventilation parameters and patients
in those areas (33). Category II
4. Coordinate system startups with infection-
control staff to protect patients in PE rooms from
bursts of fungal spores (1,3,37,47). Category IC
(AIA: 5.1, 5.2)
5. Allow sufficient time for ACH to clean the air
once the system is operational (Table 1) (1,33).
Category IC (AIA: 5.1, 5.2)
K. HVAC systems serving offices and administrative
areas may be shut down for energy conservation
purposes, but the shutdown must not alter or
adversely affect pressure differentials maintained in
laboratories or critical-care areas with specific ven-
tilation requirements (i.e., PE rooms, AII rooms,
operating rooms). Category II
L. Whenever possible, avoid inactivating or shutting
down the entire HVAC system, especially in acute-
care facilities. Category II
M.  Whenever feasible, design and install fixed backup
ventilation systems for new or renovated construc-
tion of PE rooms, AII rooms, operating rooms, and
other critical-care areas identified by ICRA (1).
Category IC (AIA: 1.5.A1)
II. Construction, Renovation, Remediation, Repair, and
Demolition
A. Establish a multidisciplinary team that includes
infection-control staff to coordinate demolition,
construction, and renovation projects and consider
proactive preventive measures at the inception; pro-
duce and maintain summary statements of the
team’s activities (1,9,11–16,38,48–51). Category IB,
IC (AIA: 5.1)
TABLE 1. Air changes/hour (ACH) and time required for
airborne-contaminant removal efficiencies of 99% and 99.9%
Time Time
(min) required (min) required
for removal for removal
ACH efficiency of 99% efficiency of 99.9%
2*† 138 207
4 69 104
6 46 69
8 35 52
10 28 41
12 23 35
15 18 28
20 14 21
50 6 8
Sources: CDC. Guidelines for preventing the transmission of
Mycobacterium tuberculosis in health-care facilities. MMWR 1994;43(No.
RR-13).
American Conference of Governmental Industrial Hygienists. HVAC
components, functions and malfunctions (Topic 8-4). In: Industrial
ventilation: a manual of recommended practice. 24th ed. Cincinnati, OH:
American Conference of Governmental Industrial Hygienists, 2001.
Mutchler JE. Principles of ventilation. In: NIOSH. The industrial
environment — its evaluation and control. Washington, DC: US
Department of Health, Education, and Welfare, Public Health Service,
1973. DHHS publication no. (NIOSH) 74-117. Available at: http://
www.cdc.gov/niosh/74-117.html.
Note: Bold entries denote frequently cited ACH for patient-care areas.
*Values were derived from the formula
t2 – t1 = –[ln (C2 / C1) / (Q / V)] × 60, with t1 = 0
where
t1 = initial timepoint (min)
t2 = final timepoint (min)
C1 = initial concentration of contaminant
C2 = final concentration of contaminant
C2 / C1 = 1 – (removal efficiency/100)
Q = air flow rate in cubic feet/hour
V = room volume in cubic feet
Q / V = ACH
† Values apply to an empty room with no aerosol-generating source. With
a person present and generating aerosol, this table would not apply.
Other equations are available that include a constant generating source.
However, certain diseases (e.g., infectious tuberculosis) are not likely
to be aerosolized at a constant rate. The times given assume perfect
mixing of the air within the space (i.e., mixing factor = 1). However,
perfect mixing usually does not occur. Removal times will be longer in
rooms or areas with imperfect mixing or air stagnation. Caution should
be exercised in using this table in such situations. For booths or other
local ventilation enclosures, manufacturers’ instructions should be
consulted.
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B. Educate both the construction team and health-care
staff in immunocompromised patient-care areas
regarding the airborne infection risks associated with
construction projects, dispersal of fungal spores
during such activities, and methods to control the
dissemination of fungal spores (11–16,27,50,52–
56). Category IB
C. Incorporate mandatory adherence agreements for
infection control into construction contracts, with
penalties for noncompliance and mechanisms to
ensure timely correction of problems (1,11,13–
16,27,50). Category IC (AIA: 5.1)
D. Establish and maintain surveillance for airborne
environmental disease (e.g., aspergillosis) as appro-
priate during construction, renovation, repair, and
demolition activities to ensure the health and safety
of immunocompromised patients (27,57–59). Cat-
egory IB
1. Using active surveillance, monitor for airborne
infections in immunocompromised patients
(27,37,57,58). Category IB
2. Periodically review the facility’s microbiologic,
histopathologic, and postmortem data to iden-
tify additional cases (27,37,57,58). Category IB
3. If cases of aspergillosis or other health-care–
associated airborne fungal infections occur,
aggressively pursue the diagnosis with tissue
biopsies and cultures as feasible (11,13–
16,27,50,57–59). Category IB
E. Implement infection-control measures relevant to
construction, renovation, maintenance, demolition,
and repair (1,16,49,50,60). Category IB, IC (AIA:
5.1, 5.2)
1. Before the project gets under way, perform an
ICRA to define the scope of the activity and the
need for barrier measures (1,11,13–16,48–
51,60). Category IB, IC (AIA: 5.1)
a. Determine if immunocompromised patients
may be at risk for exposure to fungal spores
from dust generated during the project (13–
16,48,51).
b. Develop a contingency plan to prevent such
exposures (13–16,48,51).
2. Implement infection-control measures for exter-
nal demolition and construction activities
(11,13–16,50,61,62). Category IB
a. Determine if the facility can operate tempo-
rarily on recirculated air; if feasible, seal off
adjacent air intakes.
b. If this is not possible or practical, check the
low-efficiency (roughing) filter banks fre-
quently and replace as needed to avoid
buildup of particulates.
c. Seal windows and reduce wherever possible
other sources of outside air intrusion (e.g.,
open doors in stairwells and corridors),
especially in PE areas.
3. Avoid damaging the underground water system
(i.e., buried pipes) to prevent soil and dust con-
tamination of the water (1,63). Category IB, IC
(AIA: 5.1)
4. Implement infection-control measures for inter-
nal construction activities (1,11,13–16,48–
50,64). Category IB, IC (AIA: 5.1, 5.2)
a. Construct barriers to prevent dust from con-
struction areas from entering patient-care
areas; ensure that barriers are impermeable
to fungal spores and in compliance with
local fire codes (1,45,48,49,55,64–66).
b. Seal off and block return air vents if rigid
barriers are used for containment (1,16,50).
c. Implement dust-control measures on sur-
faces and divert pedestrian traffic away from
work zones (1,48,49,64).
d. Relocate patients whose rooms are adjacent
to work zones, depending on their immune
status, the scope of the project, the potential
for generation of dust or water aerosols, and
the methods used to control these aerosols
(1,64,65).
5. Perform those engineering and work-site related
infection-control measures as needed for inter-
nal construction, repairs, and renovations
(1,48,49,51,64,66). Category IB, IC (AIA: 5.1,
5.2)
a. Ensure proper operation of the air-handling
system in the affected area after erection of
barriers and before the room or area is set to
negative pressure (39,47,50,64). Category IB
b. Create and maintain negative air pressure in
work zones adjacent to patient-care areas and
ensure that required engineering controls are
maintained (1,48,49,51,64,66).
c. Monitor negative airflow inside rigid barri-
ers (1,67).
d. Monitor barriers and ensure integrity of the
construction barriers; repair gaps or breaks
in barrier joints (1,65,66,68).
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e. Seal windows in work zones if practical; use
window chutes for disposal of large pieces
of debris as needed, but ensure that the nega-
tive pressure differential for the area is main-
tained (1,13,48).
f. Direct pedestrian traffic from construction
zones away from patient-care areas to mini-
mize dispersion of dust (1,13–16,44,48–
51,64).
g. Provide construction crews with 1) desig-
nated entrances, corridors, and elevators
wherever practical; 2) essential services (e.g.,
toilet facilities) and convenience services
(e.g., vending machines); 3) protective cloth-
ing (e.g., coveralls, footgear, and headgear)
for travel to patient-care areas; and 4) a space
or anteroom for changing clothing and stor-
ing equipment (1,11,13–16,50).
h. Clean work zones and their entrances daily
by 1) wet-wiping tools and tool carts before
their removal from the work zone; 2) plac-
ing mats with tacky surfaces inside the
entrance; and 3) covering debris and secur-
ing this covering before removing debris
from the work zone (1,11,13–16,50).
i. In patient-care areas, for major repairs that
include removal of ceiling tiles and disrup-
tion of the space above the false ceiling, use
plastic sheets or prefabricated plastic units
to contain dust; use a negative pressure sys-
tem within this enclosure to remove dust;
and either pass air through an industrial-
grade, portable HEPA filter capable of fil-
tration rates of 300–800 ft3/min., or exhaust
air directly to the outside (16,50,64,67,69).
j. Upon completion of the project, clean the
work zone according to facility procedures,
and install barrier curtains to contain dust
and debris before removing rigid barriers
(1,11,13–16,48–50).
k. Flush the water system to clear sediment
from pipes to minimize waterborne micro-
organism proliferation (1,63).
l. Restore appropriate ACH, humidity, and
pressure differential; clean or replace air fil-
ters; dispose of spent filters (3,4,28,47).
F. Use airborne-particle sampling as a tool to evaluate
barrier integrity (3,70). Category II
G. Commission the HVAC system for newly con-
structed health-care facilities and renovated spaces
before occupancy and use, with emphasis on ensur-
ing proper ventilation for operating rooms, AII
rooms, and PE areas (1,70–72). Category IC (AIA:
5.1; ASHRAE: 1-1996)
H. No recommendation is offered regarding routine
microbiologic air sampling before, during, or after
construction, or before or during occupancy of
areas housing immunocompromised patients
(9,48,49,51,64,73,74). Unresolved issue
I. If a case of health-care–acquired aspergillosis or other
opportunistic environmental airborne fungal disease
occurs during or immediately after construction,
implement appropriate follow-up measures
(40,48,75–78). Category IB
1. Review pressure-differential monitoring docu-
mentation to verify that pressure differentials in
the construction zone and in PE rooms are
appropriate for their settings (1,40,78). Category
IB, IC (AIA: 5.1)
2. Implement corrective engineering measures to
restore proper pressure differentials as needed
(1,40,78). Category IB, IC (AIA: 5.1)
3. Conduct a prospective search for additional cases
and intensify retrospective epidemiologic review
of the hospital’s medical and laboratory records
(27,48,76,79,80). Category IB
4. If no epidemiologic evidence of ongoing trans-
mission exists, continue routine maintenance in
the area to prevent health-care–acquired fungal
disease (27,75). Category IB
J. If no epidemiologic evidence exists of ongoing trans-
mission of fungal disease, conduct an environmen-
tal assessment to find and eliminate the source
(11,13–16,27,44,49–51,60,81). Category IB
1. Collect environmental samples from potential
sources of airborne fungal spores, preferably by
using a high-volume air sampler rather than settle
plates (2,4,11,13–16,27,44,49,50,64,65,81–
86). Category IB
2. If either an environmental source of airborne
fungi or an engineering problem with filtration
or pressure differentials is identified, promptly
perform corrective measures to eliminate the
source and route of entry (49,60). Category IB
3. Use an EPA-registered antifungal biocide (e.g.,
copper-8-quinolinolate) for decontaminating
structural materials (16,61,66,87). Category IB
4. If an environmental source of airborne fungi is
not identified, review infection-control mea-
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sures, including engineering controls, to iden-
tify potential areas for correction or improve-
ment (88,89). Category IB
5. If possible, perform molecular subtyping of
Aspergillus spp. isolated from patients and the
environment to compare their strain identities
(90–94). Category II
K. If air-supply systems to high-risk areas (e.g., PE
rooms) are not optimal, use portable, industrial-
grade HEPA filters on a temporary basis until rooms
with optimal air-handling systems become available
(1,13–16,27,50). Category II
III. Infection Control and Ventilation Requirements for
PE rooms
A. Minimize exposures of severely immuno-
compromised patients (e.g., solid-organ transplant
patients or allogeneic neutropenic patients) to
activities that might cause aerosolization of fungal
spores (e.g., vacuuming or disruption of ceiling tiles)
(37,48,51,73). Category IB
B. Minimize the length of time that immuno-
compromised patients in PE are outside their rooms
for diagnostic procedures and other activities
(37,62). Category IB
C. Provide respiratory protection for severely
immunocompromised patients when they must
leave PE for diagnostic procedures and other activi-
ties; consult the most recent revision of CDC’s
Guideline for Prevention of Health-Care–Associated
Pneumonia for information regarding the appropriate
type of respiratory protection. (27,37). Category II
D. Incorporate ventilation engineering specifications
and dust-controlling processes into the planning and
construction of new PE units (Figure 1). Category
IB, IC
1. Install central or point-of-use HEPA filters for
supply (incoming) air (1,2,27,48,56,70,
80,82,85,95–102). Category IB, IC (AIA: 5.1,
5.2, 7.2.D)
2. Ensure that rooms are well-sealed by 1) prop-
erly constructing windows, doors, and intake
and exhaust ports; 2) maintaining ceilings that
are smooth and free of fissures, open joints, and
crevices; 3) sealing walls above and below the
ceiling; and 4) monitoring for leakage and mak-
ing any necessary repairs (1,27,44,100,101).
Category IB, IC (AIA: 7.2.D3)
3. Ventilate the room to maintain >12 ACH
(1,27,37,100,101,103). Category IC (AIA:
7.2.D)
4. Locate air supply and exhaust grilles so that clean,
filtered air enters from one side of the room,
flows across the patient’s bed, and exits from
the opposite side of the room (1,27,100,101).
Category IC (AIA: 7.31.D1)
5. Maintain positive room air pressure (>2.5
Pa [0.01-inch water gauge]) in relation to the
corridor (1,3,27,100,101). Category IB, IC
(AIA: Table 7.2)
6. Maintain airflow patterns and monitor these on
a daily basis by using permanently installed
visual means of detecting airflow in new or reno-
vated construction, or by using other visual
methods (e.g., flutter strips or smoke tubes) in
existing PE units. Document the monitoring
results (1,13). Category IC (AIA: 7.2.D6)
7. Install self-closing devices on all room exit doors
in PE rooms (1). Category IC (AIA: 7.2.D4)
FIGURE 1. Example of positive-pressure room control for
protection from airborne environmental microbes*†
Source: Adapted from Heating/Piping/Air Conditioning (HPAC)
Engineering, October 2000, Penton Media, Inc.
Note: Stacked black boxes represent patient’s bed. Long open box with
cross-hatch represents supply air. Open boxes with single, diagonal
slashes represent air exhaust registers. Arrows indicate directions of
airflow.
*Possible uses include immunocompromised patient rooms (e.g.,
hematopoietic stem cell transplant or solid organ transplant procedure
rooms) and orthopedic operating rooms.
† Positive-pressure room engineering features include
• positive pressure (greater supply than exhaust air volume);
• pressure differential range of  2.5–8 Pa (0.01–0.03-in. water gauge),
ideal at 8 Pa;
• airflow differential >125-cfm supply versus exhaust;
• sealed room, approximately 0.5-sq. ft. leakage;
• clean to dirty airflow;
• monitoring;
• >12 air changes/hr (ACH); and
• return air if refiltered.
Monitor
Corridor
Bathroom
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E. Do not use laminar air flow systems in newly con-
structed PE rooms (99,101). Category II
F. Take measures to protect immunocompromised
patients who would benefit from a PE room and
who also have an airborne infectious disease (e.g.,
acute VZV infection or tuberculosis).
1. Ensure that the patient’s room is designed to
maintain positive pressure.
2. Use an anteroom to ensure appropriate air-
balance relationships and provide independent
exhaust of contaminated air to the outside, or
place a HEPA filter in the exhaust duct if the
return air must be recirculated (1,100) (Figure 2).
Category IC (AIA: 7.2.D1, A7.2.D)
3. If an anteroom is not available, place the patient
in AII and use portable, industrial-grade HEPA
filters to enhance filtration of spores in the room
(33). Category II
G. Maintain backup ventilation equipment (e.g., por-
table units for fans or filters) for emergency provi-
sion of required ventilation for PE areas and take
immediate steps to restore the fixed ventilation sys-
tem (1,37,47). Category IC (AIA: 5.1)
FIGURE 2. Example of airborne infection isolation (AII) room with anteroom and neutral anteroom*
Source: Used with permission from Andrew J. Streifel, M.P.H., University of Minnesota.
Note: Top diagram indicates airflow patterns when patient with only airborne infectious disease occupies room. Middle and bottom diagrams indicate
recommended airflow patterns when room is occupied by immunocompromised patient with airborne infectious disease. Stacked black boxes represent
patient beds. Long open boxes with cross-hatches represent supply air. Open boxes with single, diagonal slashes represent air exhaust registers. Arrows
indicate directions of airflow.
*AII isolation room with anteroom engineering features include
• pressure differential of 2.5 Pa (0.01-in. water gauge);
• airflow differential >125 cfm supply versus exhaust;
• sealed room with approximately 0.5-sq. ft. leakage;
• clean to dirty airflow;
• monitoring;
• >12 air exchanges/hr (ACH) new or renovation, 6 ACH existing; and
• anteroom airflow patterns
Anteroom
Corridor
Monitor
Bathroom
All only
Anteroom
Corridor
Monitor
Bathroom
Neutral anteroom
Corridor
Monitor
BathroomAII and
immunocompromised
AII and
immunocompromised
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IV. Infection-Control and Ventilation Requirements for
AII Rooms
A. Incorporate certain specifications into the planning
and construction or renovation of AII units
(1,34,100,101,104) (Figure 3). Category IB, IC
1. Maintain continuous negative air pressure (2.5
Pa [0.01 inch water gauge]) in relation to the air
pressure in the corridor; monitor air pressure
periodically, preferably daily, with audible
manometers or smoke tubes at the door (for
existing AII rooms), or with a permanently
installed visual monitoring mechanism. Docu-
ment the results of monitoring (1,100,101). Cat-
egory IC (AIA: 7.2.C7, Table 7.2)
2. Ensure that rooms are well-sealed by properly
constructing windows, doors, and air-intake and
exhaust ports; when monitoring indicates air
leakage, locate the leak and make necessary
repairs (1,99,100). Category IB, IC (AIA:
7.2.C3)
3. Install self-closing devices on all AII room exit
doors (1). Category IC (AIA: 7.2.C4)
4. Provide ventilation to ensure >12 ACH for reno-
vated rooms and new rooms, and >6 ACH for
existing AII rooms (1,34,104). Category IB, IC
(AIA: Table 7.2)
5. Direct exhaust air to the outside, away from air-
intake and populated areas. If this is not practi-
cal, air from the room can be recirculated after
passing through a HEPA filter (1,34). Category
IC (AIA: Table 7.2)
B. Where supplemental engineering controls for air
cleaning are indicated from a risk assessment of the
AII area, install UVGI units in the exhaust air ducts
of the HVAC system to supplement HEPA filtra-
tion or install UVGI fixtures on or near the ceiling
to irradiate upper room air (34). Category II
C. Implement environmental infection-control mea-
sures for persons with diagnosed or suspected air-
borne infectious diseases.
1. Use AII rooms for patients with or suspected of
having an airborne infection who also require
cough-inducing procedures, or use an enclosed
booth that is engineered to provide 1) >12 ACH;
2) air supply and exhaust rate sufficient to main-
tain a 2.5 Pa (0.01-inch water gauge) negative
pressure difference with respect to all surround-
ing spaces with an exhaust rate of >50 ft3/min;
and 3) air exhausted directly outside away from
air intakes and traffic or exhausted after HEPA
filtration before recirculation (1,34,105–107).
Category IB, IC (AIA: 7.15.E, 7.31.D23, 9.10,
Table 7.2)
2. Although airborne spread of viral hemorrhagic
fever (VHF) has not been documented in a
health-care setting, prudence dictates placing a
VHF patient in an AII room, preferably with an
anteroom, to reduce the risk of occupational
exposure to aerosolized infectious material in
blood, vomitus, liquid stool, and respiratory
secretions present in large amounts during the
end stage of a patient’s illness (108–110). Cat-
egory II
a. If an anteroom is not available, use portable,
industrial-grade HEPA filters in the patient’s
room to provide additional ACH equivalents
for removing airborne particulates.
b. Ensure that health-care workers wear face
shields or goggles with appropriate respira-
tors when entering the rooms of VHF
patients with prominent cough, vomiting,
diarrhea, or hemorrhage (109).
FIGURE 3. Example of negative-pressure room control for
airborne infection isolation (AII)*†
Source:  Adpted from Heating/Piping/Air Conditioning (HPAC)
Engineering, October 2000, Penton Media, Inc.
Note: Stacked black boxes represent patient’s bed. Long open box with
cross-hatch represents supply air. Open boxes with single, diagonal
slashes represent air exhaust registers. Arrows indicate direction of airflow.
*Possible uses include treatment or procedure rooms, bronchoscopy
rooms, and autopsy.
† Negative-pressure room engineering features include
• negative pressure (greater exhaust than supply air volume);
• pressure differential of 2.5 Pa (0.01-in. water gauge);
• airflow differential >125-cfm supply versus exhaust;
• sealed room, approximately 0.5-sq. ft. leakage;
• clean to dirty airflow;
• monitoring;
• >12 air exchanges/hr (ACH) new or renovation, 6 ACH existing; and
• exhaust to outside or HEPA-filtered if recirculated.
monitor
corridor
bathroom
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3. Place smallpox patients in negative pressure
rooms at the onset of their illness, preferably
using a room with an anteroom, if available (36).
Category II
D. No recommendation is offered regarding negative
pressure or isolation for patients with Pneumocystis
carinii pneumonia (111–113). Unresolved issue.
E. Maintain backup ventilation equipment (e.g., por-
table units for fans or filters) for emergency provi-
sion of ventilation requirements for AII rooms, and
take immediate steps to restore the fixed ventilation
system (1,34,47). Category IC (AIA: 5.1)
V. Infection-Control and Ventilation Requirements for
Operating Rooms
A. Implement environmental infection-control and
ventilation measures for operating rooms.
1. Maintain positive-pressure ventilation with
respect to corridors and adjacent areas
(1,114,115). Category IB, IC (AIA: Table 7.2)
2. Maintain >15 ACH, of which >3 ACH should
be fresh air (1,116,117). Category IC (AIA: Table
7.2)
3. Filter all recirculated and fresh air through the
appropriate filters, providing 90% efficiency
(dust-spot testing) at a minimum (1,118). Cat-
egory IC (AIA: Table 7.3)
4. In rooms not engineered for horizontal laminar
airflow, introduce air at the ceiling and exhaust
air near the floor (1,115,119). Category IC (AIA:
7.31.D4)
5. Do not use ultraviolet (UV) lights to prevent sur-
gical-site infections (115,120–126). Category IB
6. Keep operating room doors closed except for the
passage of equipment, personnel, and patients,
and limit entry to essential personnel (127,128).
Category IB
B. Follow precautionary procedures for infectious TB
patients who also require emergency surgery
(34,129,130). Category IB, IC
1. Use an N95 respirator approved by the National
Institute for Occupational Safety and Health
without exhalation valves in the operating room
(129,131). Category IC (Occupational Safety
and Health Administration [OSHA]; 29 Code
of Federal Regulations [CFR] 1910.134,139)
Online
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2. Intubate the patient in either the AII room or
the operating room; if intubating the patient in
the operating room, do not allow the doors to
open until 99% of the airborne contaminants
are removed (Table 1) (34,117). Category IB
3. When anesthetizing a patient with confirmed
or suspected TB, place a bacterial filter between
the anesthesia circuit and patient’s airway to
prevent contamination of anesthesia equipment
or discharge of tubercle bacilli into the ambient
air (130,132). Category IB
4. Extubate and allow the patient to recover in an
AII room (34,117). Category IB
5. If the patient has to be extubated in the operat-
ing room, allow adequate time for ACH to clean
99% of airborne particles from the air (Table 1),
because extubation is a cough-producing proce-
dure (34,117). Category IB
C. Use portable, industrial-grade HEPA filters tempo-
rarily for supplemental air cleaning during intuba-
tion and extubation for TB patients who require
surgery (33,34,117). Category II
1. Position the units appropriately so that all room
air passes through the filter; obtain engineering
consultation to determine the appropriate place-
ments (34). Category II
2. Switch the portable unit off during the surgical
procedure. Category II
3. Provide fresh air as per ventilation standards for
operating rooms; portable units do not meet the
requirements for the number of fresh ACH
(1,33,133). Category II
D. If possible, schedule TB patients as the last surgical
cases of the day to maximize the time available for
removal of airborne contamination. Category II
E. No recommendation is offered for performing
orthopedic implant operations in rooms supplied
with laminar airflow (118,120). Unresolved issue
F. Maintain backup ventilation equipment (e.g., por-
table units for fans or filters) for emergency ventila-
tion of operating rooms, and take immediate steps
to restore the fixed ventilation system
(1,47,131,134). Category IB, IC (AIA: 5.1)
VI. Other Potential Infectious Aerosol Hazards in
Health-Care Facilities
A. In settings where surgical lasers are used, wear
appropriate personal protective equipment (PPE),
including N95 or N100 respirators, to minimize
exposure to laser plumes (129,135,136). Category
IC (OSHA; 29 CFR 1910.134,139)
B. Use central wall suction units with in-line filters to evacu-
ate minimal laser plumes (135–138). Category II
C. Use a mechanical smoke evacuation system with a
high-efficiency filter to manage the generation of
large amounts of laser plume, when ablating tissue
infected with human papilloma virus (HPV) or per-
forming procedures on a patient with extrapul-
monary TB (34,136,137,139–141). Category II
Recommendations — Water
I. Controlling the Spread of Waterborne Micro-
organisms
A. Practice hand hygiene to prevent the hand transfer
of waterborne pathogens, and use barrier precau-
tions (e.g., gloves) as defined by other guidelines
(36,142–146). Category IA
B. Eliminate contaminated water or fluid environmen-
tal reservoirs (e.g., in equipment or solutions) wher-
ever possible (142,147). Category IB
C. Clean and disinfect sinks and wash basins on a regu-
lar basis by using an EPA-registered product as set
by facility policies. Category II
D. Evaluate for possible environmental sources (e.g.,
potable water) of specimen contamination when
waterborne microorganisms (e.g., NTM) of unlikely
clinical importance are isolated from clinical cultures
(e.g., specimens collected aseptically from sterile sites
or, if postprocedural, colonization after use of tap
water in patient care) (148–151). Category IB
E. Avoid placing decorative fountains and fish tanks
in patient-care areas; ensure disinfection and foun-
tain maintenance if decorative fountains are used in
public areas of the health-care facility (152). Cat-
egory IB
II. Routine Prevention of Waterborne Microbial
Contamination Within the Distribution System
A. Maintain hot water temperature at the return at the
highest temperature allowable by state regulations
or codes, preferably >124ºF (>51ºC), and maintain
cold water temperature at <68ºF (<20ºC) (27,153).
Category IC (States; ASHRAE: 12:2000)
B. If the hot water temperature can be maintained at
>124ºF (>51ºC), explore engineering options (e.g.,
installing preset thermostatic valves in point-of-use
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fixtures) to help minimize the risk of scalding (153).
Category II
C. When state regulations or codes do not allow hot
water temperatures above the range of 105ºF–120ºF
(40.6ºC–49ºC) for hospitals or 95ºF–110ºF (35ºC–
43.3ºC) for nursing care facilities or when build-
ings cannot be retrofitted for thermostatic mixing
valves, follow either of these alternative preventive
measures to minimize the growth of Legionella spp.
in water systems. Category II
1. Periodically increase the hot water temperature
to >150ºF (>66ºC) at the point of use (153).
Category II
2. Alternatively, chlorinate the water and then flush
it through the system (153–155). Category II
D. Maintain constant recirculation in hot-water distri-
bution systems serving patient-care areas (1). Cat-
egory IC (AIA: 7.31.E.3)
III. Remediation Strategies for Distribution System
Repair or Emergencies
A. Whenever possible, disconnect the ice machine
before planned water disruptions. Category II
B. Prepare a contingency plan to estimate water
demands for the entire facility in advance of signifi-
cant water disruptions (i.e., those expected to result
in extensive and heavy microbial or chemical con-
tamination of the potable water), sewage intrusion,
or flooding (45,156). Category IC (JCAHO: EC 1.4)
C. When a significant water disruption or an emer-
gency occurs, adhere to any advisory to boil water
issued by the municipal water utility (157). Cat-
egory IB, IC (Municipal order)
1. Alert patients, families, staff, and visitors not to
consume water from drinking fountains, ice, or
drinks made from municipal tap water, while
the advisory is in effect, unless the water has been
disinfected (e.g., by bringing to a rolling boil
for >1 minute) (157). Category IB, IC (Munici-
pal order)
2. After the advisory is lifted, run faucets and drink-
ing fountains at full flow for >5minutes, or use
high-temperature water flushing or chlorination
(153,157). Category IC, II (Municipal order;
ASHRAE: 12:2000)
D. Maintain a high level of surveillance for waterborne
disease among patients after a boil water advisory is
lifted. Category II
E. Corrective decontamination of the hot water sys-
tem might be necessary after a disruption in service
or a cross-connection with sewer lines has occurred.
1. Decontaminate the system when the fewest
occupants are present in the building (e.g., nights
or weekends) (27,153). Category IC (ASHRAE:
12:2000)
2. If using high-temperature decontamination, raise
the hot-water temperature to 160ºF–170ºF
(71ºC–77ºC) and maintain that level while pro-
gressively flushing each outlet around the sys-
tem for >5 minutes (27,153). Category IC
(ASHRAE: 12:2000)
3. If using chlorination, add enough chlorine, pref-
erably overnight, to achieve a free chlorine
residual of >2 mg/L (>2 ppm) throughout the
system (153). Category IC (ASHRAE: 12:2000)
a. Flush each outlet until chlorine odor is
detected.
b. Maintain the elevated chlorine concentration
in the system for >2 (but <24 hrs).
4. Use a thorough flushing of the water system
instead of chlorination if a highly chlorine-
resistant microorganism (e.g., Cryptosporidium
spp.) is suspected as the water contaminant. Cat-
egory II
F. Flush and restart equipment and fixtures according
to manufacturer’s instructions. Category II
G. Change the pretreatment filter and disinfect the
dialysis water system with an EPA-registered prod-
uct to prevent colonization of the reverse osmosis
membrane and downstream microbial contamina-
tion (158). Category II
H. Run water softeners through a regeneration cycle to
restore their capacity and function. Category II
I. If the facility has a water-holding reservoir or
water-storage tank, consult the facility engineer or
local health department to determine whether this
equipment needs to be drained, disinfected with an
EPA-registered product, and refilled. Category II
J. Implement facility procedures to manage a sewage
system failure or flooding (e.g., arranging with other
health-care facilities for temporary transfer of
patients or provision of services), and establish com-
munications with the local municipal water utility
and the local health department to ensure that advi-
sories are received in a timely manner after release
(45,156). Category IC (JCAHO: EC 1.4; Munici-
pal order)
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K. Implement infection-control measures during sew-
age intrusion, flooding, or other water-related emer-
gencies.
1. Relocate patients and clean or sterilize supplies
from affected areas. Category II
2. If hands are not visibly soiled or contaminated
with proteinaceous material, include an alcohol-
based hand rub in the hand hygiene process 1)
before performing invasive procedures; 2)
before and after each patient contact; and 3)
whenever hand hygiene is indicated (146). Cat-
egory II
3. If hands are visibly soiled or contaminated with
proteinaceous material, use soap and bottled
water for handwashing (146). Category II
4. If the potable water system is not affected by
flooding or sewage contamination, process sur-
gical instruments for sterilization according to
standard procedures. Category II
5. Contact the manufacturer of the automated en-
doscope reprocessor (AER) for specific instruc-
tions on the use of this equipment during a water
advisory. Category II
L. Remediate the facility after sewage intrusion, flood-
ing, or other water-related emergencies.
1. Close off affected areas during cleanup proce-
dures. Category II
2. Ensure that the sewage system is fully functional
before beginning remediation so contaminated
solids and standing water can be removed. Cat-
egory II
3. If hard-surfaced equipment, floors, and walls
remain in good repair, ensure that these are dry
within 72 hours; clean with detergent according
to standard cleaning procedures. Category II
4. Clean wood furniture and materials (if still in
good repair); allow them to dry thoroughly
before restoring varnish or other surface coat-
ings. Category II
5. Contain dust and debris during remediation and
repair as outlined in air recommendations (Air:
IIG 4, 5). Category II
M. Regardless of the original source of water damage
(e.g., flooding versus water leaks from point-of-use
fixtures or roofs), remove wet, absorbent structural
items (e.g., carpeting, wallboard, and wallpaper) and
cloth furnishings if they cannot be easily and thor-
oughly cleaned and dried within 72 hours (e.g.,
moisture content <20% as determined by moisture
meter readings); replace with new materials as soon
as the underlying structure is declared by the facil-
ity engineer to be thoroughly dry (2,47,159,160).
Category IB
IV. Additional Engineering Measures as Indicated by
Epidemiologic Investigation for Controlling Water-
borne, Health-Care–Associated Legionnaires Disease
A. When using a pulse or one-time decontamination
method, superheat the water by flushing each out-
let for >5 minutes with water at 160ºF–170ºF
(71ºC–77ºC) or hyperchlorinate the system by flush-
ing all outlets for >5 minutes with water containing
>2 mg/L (>2 ppm) free residual chlorine using a
chlorine-based product registered by the EPA for
water treatment (e.g., sodium hypochlorite [chlo-
rine bleach]) (153,155,161–164). Category IB
B. After a pulse treatment, maintain both the heated
water temperature at the return and the cold water
temperature per the recommendation (Water: II A)
wherever practical and permitted by state codes, or
chlorinate heated water to achieve 1–2 mg/L (1–2
ppm) free residual chlorine at the tap by using a
chlorine-based product registered by the EPA for
water treatment (e.g., sodium hypochlorite [bleach])
(153,165–169). Category IC (States; ASHRAE:
12:2000)
C. Explore engineering or educational options (e.g.,
install preset thermostatic mixing valves in point-
of-use fixtures or post warning signs at each outlet)
to minimize the risk of scalding for patients, visi-
tors, and staff. Category II
D. No recommendation is offered for treating water in
the facility’s distribution system with chlorine
dioxide, heavy-metal ions (e.g., copper or silver),
monochloramines, ozone, or UV light (170–188).
Unresolved issue
V. General Infection-Control Strategies for Preventing
Legionnaires Disease
A. Conduct an infection-control risk assessment of the
facility to determine if patients at risk or severely
immunocompromised patients are present
(27,189,190). Category IB
B. Implement general strategies for detecting and pre-
venting Legionnaires disease in facilities that do not
provide care for severely immunocompromised
patients (i.e., facilities that do not have HSCT or
solid-organ transplant programs) (see Appendix)
(27,189,190). Category IB
1. Establish a surveillance process to detect
health-care–associated Legionnaires disease
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(27,189,190). Category IB
2. Inform health-care personnel (e.g., infection
control, physicians, patient-care staff, engineer-
ing) regarding the potential for Legionnaires
disease to occur and measures to prevent and
control health-care–associated legionellosis
(166,191). Category IB
3. Establish mechanisms to provide clinicians with
laboratory tests (e.g., culture, urine antigen,
direct fluorescence assay [DFA], and serology)
for the diagnosis of Legionnaires disease
(27,189). Category IB
C. Maintain a high index of suspicion for health-care–
associated Legionnaires disease, and perform labo-
ratory diagnostic tests for legionellosis on suspected
cases, especially in patients at risk who do not
require a PE for care (e.g., patients receiving sys-
temic steroids; patients aged >65 years; or patients
with chronic underlying disease (e.g., diabetes melli-
tus, congestive heart failure, or chronic obstructive
lung disease) (27,166,190,192–198). Category IA
D. Periodically review the availability and clinicians’
use of laboratory diagnostic tests for Legionnaires
disease in the facility; if clinicians’ use of the tests
on patients with diagnosed or suspected pneumo-
nia is limited, implement measures (e.g., an educa-
tional campaign) to enhance clinicians’ use of the
test(s) (193). Category IB
E. If one case of laboratory-confirmed, health-care–
associated Legionnaires disease is identified, or if
two or more cases of laboratory-suspected, health-
care-associated Legionnaires disease occur during a
6-month period, certain activities should be initi-
ated (181,189,191,193,199,200). Category IB
1. Report the cases to state and local health
departments where required. Category IC
(States)
2. If the facility does not treat severely immuno-
compromised patients, conduct an epidemio-
logic investigation, including retrospective
review of microbiologic, serologic, and postmor-
tem data to look for previously unidentified cases
of health-care–associated Legionnaires disease,
and begin intensive prospective surveillance for
additional cases (27,181,189,191,193,199,200).
Category IB
3. If no evidence of continued health-care–
associated transmission exists, continue inten-
sive prospective surveillance for >2 months
after the initiation of surveillance (27,181,
189,191,193,199,200). Category IB
F. If there is evidence of continued health-care–
associated transmission (i.e., an outbreak), conduct
an environmental assessment to determine the source
of Legionella spp. (199–207). Category IB
1. Collect water samples from potential aerosolized
water sources (Box 1 and Box 2) (208). Cat-
egory IB
2. Save and subtype isolates of Legionella spp.
obtained from patients and the environment
(163,199–207,209). Category IB
3. If a source is identified, promptly institute
water system decontamination measures per rec-
ommendations (see Water IV) (164,210). Cat-
egory IB
BOX 1. Potential sampling sites for Legionella spp. in health-
care facilities
Potable water system
• incoming water main
• water softener
• holding tanks, cisterns
• water heater tanks (at the inflows and outflows)
Potable water outlets, especially those in or near
patient rooms
• faucets or taps
• showers
Cooling tower, evaporative condenser
• makeup water (e.g., added to replace water lost because
of evaporation, drift, leakage)
• basin (i.e., area under the tower for collection of cooled
water)
• sump (i.e., section of basin from which cooled water
returns to heat source)
• heat sources (e.g., chillers)
Humidifiers (e.g., nebulizers)
• bubblers for oxygen
• water used for respiratory therapy equipment
Other sources
• decorative fountains
• irrigation equipment
• fire sprinkler system (if recently used)
• whirlpools, spas
Source: Barbaree JM, Gorman GW, Martin WT, Fields BS, Morrill WE.
Protocol for sampling environmental sites for legionellae. Appl Environ
Microbiol 1987;53:1454–8.
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4. If Legionella spp. are detected in >1 culture (e.g.,
conducted at 2-week intervals during 3 months),
reassess the control measures, modify them
accordingly, and repeat the decontamination
procedures; consider intensive use of techniques
used in the initial decontamination, or a com-
bination of superheating and hyperchlorination
(27,210,211). Category IB
G. If an environmental source is not identified during
a Legionnaires disease outbreak, continue surveil-
lance for new cases for >2 months. Either defer
decontamination pending identification of the
source of Legionella spp. or proceed with decontami-
nation of the hospital’s water distribution system,
with special attention to areas involved in the out-
break. Category II
H. No recommendation is offered regarding routine
culturing of water systems in health-care facilities
that do not have patient-care areas (i.e., PE or trans-
plant units) for persons at high risk for Legionella
spp. infection (see Appendix) (161,165,167,
198,212–214). Unresolved issue
I. No recommendation is offered regarding the removal
of faucet aerators in areas for immunocompetent
patients. Unresolved issue
J. Keep adequate records of all infection-control mea-
sures and environmental test results for potable
water systems. Category II
VI. Preventing Legionnaires Disease in Protective
Environments and Transplant Units
A. When implementing strategies for preventing
Legionnaires disease among severely immuno-
compromised patients housed in facilities with
HSCT or solid-organ transplant programs, incor-
porate these specific surveillance and epidemiologic
measures in addition to the steps outlined previously
(see Appendix).
1. Maintain a high index of suspicion for
legionellosis in transplant patients even when
environmental surveillance cultures do not yield
legionellae (189,215). Category IB
2. If a case occurs in a severely immuno-
compromised patient, or if severely immuno-
compromised patients are present in high-risk
areas of the hospital (e.g., PE or transplant units)
and cases are identified elsewhere in the facility,
conduct a combined epidemiologic and envi-
ronmental investigation to determine the source
of Legionella spp. (189,210). Category IB
B. Implement culture strategies and potable water and
fixture treatment measures in addition to those pre-
vious outlined (Water: V). Category II
1. Depending on state regulations on potable wa-
ter temperature in public buildings (216), hos-
pitals housing patients at high risk for
health-care–associated legionellosis should either
maintain heated water with a minimum return
temperature of >124ºF (>51ºC) and cold water
at <68ºF (<20ºC), or chlorinate heated water to
achieve 1–2 mg/L (1–2 ppm) of free residual
chlorine at the tap (153–155,165,167–
169,217). Category II
BOX 2. Procedures for collecting and processing
environmental specimens for Legionella spp
1. Collect water (1-liter samples, if possible) in sterile,
screw-top bottles.
2. Collect culture swabs of internal surfaces of faucets,
aerators, and shower heads in a sterile, screw-top
container (e.g., 50 mL plastic centrifuge tube).
Submerge each swab in 5–10 mL of sample water taken
from the same device from which the sample was
obtained.
3. Transport samples and process in a laboratory proficient
at culturing water specimens for Legionella spp, as soon
as possible after collection.*
4. Test samples for the presence of Legionella spp. by using
semiselective culture media using procedures specific
to the cultivation and detection of Legionella spp.†§
Sources: Barbaree JM, Gorman GW, Martin WT, Fields BS, Morrill
WE. Protocol for sampling environmental sites for legionellae. Appl
Environ Microbiol 1987;53:1454–8.
CDC. Procedures for the recovery of Legionella from the environment.
Atlanta GA: US Department of Health and Human Services, Public
Health Service, 1992:1–13.
Alary MA, Joly JR. Comparison of culture methods and an
immunofluorescence assay for the detection of Legionella pneumophila in
domestic hot water devices. Curr Microbiol 1992;24:19–25.
Vickers RM, Stout JE, Yu VL. Failure of a diagnostic monoclonal
immunofluorescent reagent to detect Legionella pneumophila in
environmental samples. Appl Environ Microbiol 1990;56:2912–4.
Flournoy DJ, Belobraydic KA, Silberg SL, Lawrence CH, Guthrie PJ.
False positive Legionella pneumophila direct immunofluorescence
monoclonal antibody test caused by Bacillus cereus spores. Diag Microbiol
Infect Dis 1988;9:123–5.
Bej AK, Majbubani MH, Atlas RM. Detection of viable Legionella
pneumophila in water by polymerase chain reaction and gene probe
methods. Appl Environ Microbiol 1991;57:597–600.
* Samples may be transported at room temperature but must be protected
from temperature extremes. Samples not processed within 24 hours of
collection should be refrigerated.
† Detection of Legionella spp. antigen by the direct fluorescent antibody
technique is not suitable for environmental samples.
§ Use of polymerase chain reaction for identification of Legionella spp. is
not recommended until more data regarding the sensitivity and
specificity of this procedure are available.
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2. Periodic culturing for legionellae in potable
water samples from HSCT or solid-organ trans-
plant units can be performed as part of a com-
prehensive strategy to prevent Legionnaires
disease in these units (37,154,189,218). Cat-
egory II
3. No recommendation is offered regarding the
optimal methodology (i.e., frequency or num-
ber of sites) for environmental surveillance cul-
tures in HSCT or solid-organ transplant units.
Unresolved issue
4. In areas with patients at risk, when Legionella
spp. are not detectable in unit water, remove,
clean, and disinfect shower heads and tap aera-
tors monthly by using a chlorine-based, EPA-
registered product. If an EPA-registered chlorine
disinfectant is not available, use a chlorine bleach
solution (500–615 ppm [1:100 v/v dilution])
(153,187). Category II
C. If Legionella spp. are determined to be present in
the water of a transplant unit, implement certain
measures until Legionella spp. are no longer detected
by culture.
1. Decontaminate the water supply as outlined
previously (Water: IV) (27,37,153,164,210).
Category IB
2. Do not use water from the faucets in patient-
care rooms to avoid creating infectious aerosols
(37,219). Category IB
3. Restrict severely immunocompromised patients
from taking showers (37,219). Category IB
4. Use water that is not contaminated with
Legionella spp. for HSCT patients’ sponge baths
(37,219). Category IB
5. Provide patients with sterile water for tooth
brushing, drinking, and for flushing nasogastric
tubing during legionellosis outbreaks (37,219).
Category IB
D. Do not use large-volume room air humidifiers that
create aerosols (e.g., by Venturi principle, ultrasound,
or spinning disk) unless they are subjected to high-
level disinfection and filled only with sterile water
(27,37,201,220). Category IB
VII. Cooling Towers and Evaporative Condensers
A. When planning construction of new health-care
facilities, locate cooling towers so that the drift is
directed away from the air-intake system, and
design the towers to minimize the volume of aero-
sol drift (153,203,221). Category IC (ASHRAE 12-
2000)
B. Implement infection-control procedures for opera-
tional cooling towers (153,203,222). Category IC
(ASHRAE 12-2000)
1. Install drift eliminators (153,203,222). Category
IC (ASHRAE 12-2000)
2. Use an effective EPA-registered biocide on a
regular basis (153). Category IC (ASHRAE 12-
2000)
3. Maintain towers according to manufacturers’
recommendations, and keep detailed mainte-
nance and infection-control records, including
environmental test results from legionellosis
outbreak investigations (153). Category IC
(ASHRAE 12-2000)
C. If cooling towers or evaporative condensers are
implicated in health-care–associated legionellosis,
decontaminate the cooling-tower system
(199,203,221,223). Category IB
VIII. Dialysis Water Quality and Dialysate
A. Adhere to current AAMI standards for quality-
assurance performance of devices and equipment
used to treat, store, and distribute water in hemodi-
alysis centers (both acute and maintenance [chronic]
settings) and for the preparation of concentrates and
dialysate (224–235). Category IA, IC (AAMI:
American National Standards Institute [ANSI]/
AAMI RD5:1992, ANSI/AAMI RD47:1993)
B. No recommendation is offered regarding whether
more stringent requirements for water quality should
be imposed in hemofiltration and hemodiafiltration.
Unresolved issue
C. Conduct microbiologic testing specific to water in
dialysis settings (229,230,236–238). Category IA,
IC (AAMI: ANSI/AAMI RD5:1992, ANSI/AAMI
RD47:1993, RD62:2001)
1. Perform bacteriologic assays of water and dialy-
sis fluids at least once a month and during out-
breaks by using standard quantitative methods
(236–238). Category IA, IC (AAMI: ANSI/
AAMI RD62:2001)
a. Assay for heterotrophic, mesophilic bacteria
(e.g., Pseudomonas spp).
b. Do not use nutrient-rich media (e.g., blood
agar or chocolate agar).
2. In conjunction with microbiologic testing, per-
form endotoxin testing on product water used
to reprocess dialyzers for multiple use
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(229,230,239–242). Category IA, IC (AAMI:
ANSI/AAMI RD5:1992, ANSI/AAMI
RD47:1993)
3. Ensure that water does not exceed the limits for
microbial counts and endotoxin concentrations
(Table 2) (229–231). Category IA, IC (AAMI:
ANSI/AAMI RD5:1992, ANSI/AAMI
RD47:1993)
D. Disinfect water distribution systems in dialysis set-
tings at least weekly (226–228,231,236). Category
IA, IC (AAMI: ANSI/AAMI RD62:2001)
E. Wherever practical, design and engineer water sys-
tems in dialysis settings to avoid incorporating joints,
dead-end pipes, and unused branches and taps that
can harbor bacteria (226– 228,231,236). Category
IA, IC (AAMI: ANSI/AAMI RD62:2001)
F. When storage tanks are used in dialysis systems, they
should be routinely drained, disinfected with an
EPA-registered product, and fitted with an ultrafil-
ter or pyrogenic filter (membrane filter with a pore
size sufficient to remove particles and molecules >1
kilodalton) installed in the water line distal to the
storage tank (236). Category IC (AAMI: ANSI/
AAMI RD62:2001)
IX. Ice Machines and Ice
A. Do not handle ice directly by hand, and wash hands
before obtaining ice. Category II
B. Use a smooth-surface ice scoop to dispense ice
(243,244). Category II
1. Keep the ice scoop on a chain short enough that
the scoop cannot touch the floor or keep the
scoop on a clean, hard surface when not in use
(243,244). Category II
2. Do not store the ice scoop in the ice bin. Cat-
egory II
C. Do not store pharmaceuticals or medical solutions
on ice intended for consumption; use sterile ice to
keep medical solutions cold, or use equipment spe-
cifically manufactured for this purpose (244,245).
Category IB
D. Machines that dispense ice are preferred to those
that require ice to be removed from bins or chests
with a scoop (246,247). Category II
E. Limit access to ice-storage chests, and keep container
doors closed except when removing ice (244). Cat-
egory II
F. Clean, disinfect, and maintain ice-storage chests on
a regular basis. Category II
1. Follow the manufacturer’s instructions for clean-
ing. Category II
2. Use an EPA-registered disinfectant suitable for
use on ice machines, dispensers, or storage chests
in accordance with label instructions. Category II
3. If instructions and EPA-registered disinfectants
suitable for use on ice machines are not avail-
able, use a general cleaning/disinfecting regimen
(Box 3) (244). Category II
4. Flush and clean ice machines and dispensers if
they have not been disconnected before antici-
pated lengthy water disruptions. Category II
G. Install proper air gaps where the condensate lines
meet the waste lines. Category II.
H. Conduct microbiologic sampling of ice, ice chests,
and ice-making machines and dispensers where
indicated during an epidemiologic investigation
(244,248,249). Category IB
X. Hydrotherapy Tanks and Pools
A. Drain and clean hydrotherapy equipment (e.g.,
Hubbard tanks, tubs, whirlpools, whirlpool spas, or
birthing tanks) after each patient’s use, and disin-
fect equipment surfaces and components by using
an EPA-registered product in accordance with the
manufacturer’s instructions. Category II
TABLE 2. Microbiologic limits for hemodialysis fluids
Maximum total Maximum
heterotrophs endotoxin level
Hemodialysis fluid (CFU/mL*) (EU/mL†)
Present standards
Product water§
  Used to prepare dialysate 200 No standard
  Used to reprocess dialyzers 200 5
Dialysate 2,000 No standard
Proposed standards¶
Product water 200 2
Dialysate 200 2
Sources: American National Standards Institute, Association for the
Advancement of Medical Instrumentation. Hemodialysis Systems. ANSI/
AAMI RD5-1992. Arlington, VA: Association for the Advancement of
Medical Instrumentation, 1993.
American National Standards Institute, Association for the Advancement
of Medical Instrumentation. Reuse of hemodialyzers. ANSI/AAMI RD47-
1993. Arlington, VA: Association for the Advancement of Medical
Instrumentation, 1993.
* Colony forming units/milliliter.
† Endotoxin units/milliliter.
§ Product water presently includes water used to prepare dialysate and
water used for reprocessing dialyzers.
¶ Dialysate for hemodialysis, RD52, under development, American National
Standards Institute, Association for the Advancement of Medical
Instrumentation (AAMI).
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B. In the absence of an EPA-registered product for water
treatment, add sodium hypochlorite to the water:
1. Maintain a 15-ppm chlorine residual in the
water of small hydrotherapy tanks, Hubbard
tanks, and tubs (250). Category II
2. Maintain a 2–5-ppm chlorine residual in the
water of whirlpools and whirlpool spas (251).
Category II
3. If the pH of the municipal water is in the basic
range (e.g., when chloramine is used as the pri-
mary drinking water disinfectant in the com-
munity), consult the facility engineer regarding
the possible need to adjust the pH of the water
to a more acidic level before disinfection, to
enhance the biocidal activity of the chlorine
(252). Category II
C. Clean and disinfect hydrotherapy equipment after
using tub liners. Category II
D. Clean and disinfect inflatable tubs unless they are
single-use equipment. Category II
E. No recommendation is offered regarding the use of
antiseptic chemicals (e.g., chloramine-T) in the
water during hydrotherapy sessions. Unresolved
issue
F. Conduct a risk assessment of patients before their
use of large hydrotherapy pools, deferring patients
with draining wounds or fecal incontinence from
pool use until their condition resolves. Category II
G. For large hydrotherapy pools, use pH and chlorine
residual levels appropriate for an indoor pool as pro-
vided by local and state health agencies. Category
IC (States)
H. No recommendation is offered regarding the use in
health-care settings of whirlpool or spa equipment
manufactured for home or recreational use. Unre-
solved issue
XI. Miscellaneous Medical Equipment Connected to
Water Systems
A. Clean, disinfect, and maintain AER equipment
according to the manufacturer’s instructions and rel-
evant scientific literature to prevent inadvertent con-
tamination of endoscopes and bronchoscopes with
waterborne microorganisms (253–257). Category IB
1. To rinse disinfected endoscopes and
bronchoscopes, use water of the highest quality
practical for the system’s engineering and
design (e.g., sterile water or bacteriologically fil-
tered water [water filtered through 0.1–0.2-µm
filters]) (254,256–258). Category IB
2. Dry the internal channels of the reprocessed
endoscope or bronchoscope by using a proven
method (e.g., 70% alcohol followed by forced-
air treatment) to lessen the potential for prolif-
eration of waterborne microorganisms and to
help prevent biofilm formation (259–263). Cat-
egory IB
B. Use water that meets nationally recognized standards
set by the EPA for drinking water (<500 CFU/mL
for heterotrophic plate count) for routine dental
BOX 3 . General steps for cleaning and maintaining ice
machines, dispensers, and storage chests*
 1. Disconnect unit from power supply.
 2. Remove and discard ice from bin or storage chest.
 3. Allow unit to warm to room temperature.
 4. Disassemble removable parts of machine that make
contact with water to make ice.
 5. Thoroughly clean machine and parts with water and
detergent.
 6. Dry external surfaces of removable parts before
reassembling.
 7. Check for any needed repair.
 8. Replace feeder lines as appropriate (e.g., when
damaged, old, or difficult to clean).
 9. Ensure presence of an air space in tubing leading from
water inlet into water distribution system of machine.
10. Inspect for rodent or insect infestations under the
unit and treat as needed.
11. Check door gaskets (open compartment models) for
evidence of leakage or dripping into the storage chest.
12. Clean the ice-storage chest or bin with fresh water
and detergent; rinse with fresh tap water.
13. Sanitize machine by circulating a 50–100 parts per
million (ppm) solution of sodium hypochlorite (i.e.,
4–8 mL sodium hypochlorite/gallon of water)
through the ice-making and storage systems for 2
hours (100 ppm solution), or 4 hours (50 ppm
solution).
14. Drain sodium hypochlorite solution and flush with
fresh tap water.
15. Allow all surfaces of equipment to dry before
returning to service.
Source: Adapted from Manangan LP, Anderson RL, Arduino MJ, Bond
WW. Sanitary care and maintenance of ice-storage chests and ice-making
machines in health care facilities. Am J Infect Control 1998;26:111-2.
* These general instructions should be used only where manufacturer-
recommended methods and EPA-registered disinfectants are not
available.
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treatment output water (264–267). Category IC
(EPA: 40 CFR 1 Part 141, Subpart G)
C. Take precautions to prevent waterborne contami-
nation of dental unit water lines and instruments.
1. After each patient, discharge water and air for a
minimum of 20–30 seconds from any dental
device connected to the dental water system that
enters a patient’s mouth (e.g., handpieces,
ultrasonic scalers, or air/water syringes)
(265,268). Category II
2. Consult with dental water-line manufacturers
to 1) determine suitable methods and equipment
to obtain the recommended water quality; and
2) determine appropriate methods for monitor-
ing the water to ensure quality is maintained
(265,269). Category II
3. Consult with the dental unit manufacturer
regarding the need for periodic maintenance of
antiretraction mechanisms (268,269). Category IB
Recommendations —
Environmental Services
I. Cleaning and Disinfecting Strategies for Environ-
mental Surfaces in Patient-Care Areas
A. Select EPA-registered disinfectants, if available, and
use them in accordance with the manufacturer’s
instructions (270–272). Category IC (EPA: 7 United
States Code [USC] § 136 et seq.)
B. Do not use high-level disinfectants/liquid chemical
sterilants for disinfection of either noncritical
instruments and devices or any environmental sur-
faces; such use is counter to label instructions for
these toxic chemicals (273–278). Category IC (Food
and Drug Administration [FDA]: 21 CFR 801.5,
807.87.e)
C. Follow manufacturers’ instructions for cleaning and
maintaining noncritical medical equipment. Cat-
egory II
D. In the absence of a manufacturer’s cleaning instruc-
tions, follow certain procedures.
1. Clean noncritical medical equipment surfaces
with a detergent/disinfectant. This may be fol-
lowed by an application of an EPA-registered
hospital disinfectant with or without a tubercu-
locidal claim (depending on the nature of the
surface and the degree of contamination), in
accordance with germicide label instructions
(274). Category II
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2. Do not use alcohol to disinfect large environ-
mental surfaces (273). Category II
3. Use barrier protective coverings as appropriate
for noncritical surfaces that are 1) touched fre-
quently with gloved hands during the delivery
of patient care; 2) likely to become contaminated
with blood or body substances; or 3) difficult to
clean (e.g., computer keyboards) (265). Category II
E. Keep housekeeping surfaces (e.g., floors, walls, table-
tops) visibly clean on a regular basis and clean up
spills promptly (279). Category II
1. Use a one-step process and an EPA-registered
hospital detergent/disinfectant designed for gen-
eral housekeeping purposes in patient-care areas
where 1) uncertainty exists as to the nature of
the soil on the surfaces (e.g., blood or body fluid
contamination versus routine dust or dirt); or
2) uncertainty exists regarding the presence of
multidrug resistant organisums on such surfaces
(272,274,280,281). Category II
2. Detergent and water are adequate for cleaning
surfaces in nonpatient-care areas (e.g., adminis-
trative offices). Category II
3. Clean and disinfect high-touch surfaces (e.g.,
doorknobs, bed rails, light switches, and surfaces
in and around toilets in patients’ rooms) on a
more frequent schedule than minimal-touch
housekeeping surfaces. Category II
4. Clean walls, blinds, and window curtains in
patient-care areas when they are visibly dusty or
soiled (270,282–284). Category II
F. Do not perform disinfectant fogging in patient-care
areas (270,285). Category IB
G. Avoid large-surface cleaning methods that produce
mists or aerosols, or disperse dust in patient-care
areas (37,48,51,73). Category IB
H. Follow proper procedures for effective uses of mops,
cloths, and solutions. Category II
1. Prepare cleaning solutions daily or as needed,
and replace with fresh solution frequently
according to facility policies and procedures
(280,281). Category II
2. Change the mop head at the beginning of each
day and also as required by facility policy, or
after cleaning up large spills of blood or other
body substances. Category II
3. Clean mops and cloths after use and allow to
dry before reuse; or use single-use, disposable mop
heads and cloths (282,286–288). Category II
I. After the last surgical procedure of the day or night,
wet vacuum or mop operating room floors with a
single-use mop and an EPA-registered hospital dis-
infectant (114). Category IB
J. Do not use mats with tacky surfaces at the entrances
to operating rooms or infection-control suites (114).
Category IB
K. Use appropriate dusting methods for patient-care
areas designated for immunocompromised patients
(e.g., HSCT patients) (37,40,280). Category IB
1. Wet-dust horizontal surfaces daily by moisten-
ing a cloth with a small amount of an EPA-
registered hospital detergent/disinfectant
(37,40,280). Category IB
2. Avoid dusting methods that disperse dust (e.g.,
feather-dusting) (40). Category IB
L. Keep vacuums in good repair and equip vacuums
with HEPA filters for use areas with patients at risk
(37,40,280,289). Category IB
M. Close the doors of immunocompromised patients’
rooms when vacuuming, waxing, or buffing corri-
dor floors to minimize exposure to airborne dust
(37,40,289). Category IB
N. When performing low- or intermediate-level disin-
fection of environmental surfaces in nurseries and
neonatal units, avoid unnecessary exposure of neo-
nates to disinfectant residues on these surfaces by
using EPA-registered germicides in accordance with
manufacturers’ instructions and safety advisories
(271,290–292). Category IB, IC (EPA: 7 USC §
136 et seq.)
1. Do not use phenolics or any other chemical ger-
micide to disinfect bassinets or incubators dur-
ing an infant’s stay (271,290–292). Category IB
2. Rinse disinfectant-treated surfaces, especially
those treated with phenolics, with water (290–
292). Category IB
O. When using phenolic disinfectants in neonatal units,
prepare solutions to correct concentrations in
accordance with manufacturers’ instructions, or use
premixed formulations (271,290–292). Category
IB, IC (EPA: 7 USC § 136 et seq.)
II. Cleaning Spills of Blood and Body Substances
A. Promptly clean and decontaminate spills of blood
or other potentially infectious materials (293–300).
Category IB, IC (OSHA: 29 CFR 1910.1030 §
d.4.ii.A)
B. Follow proper procedures for site decontamination
of spills of blood or blood-containing body fluids
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(293–300). Category IC (OSHA: 29 CFR
1910.1030 § d.4.ii.A)
1. Use protective gloves and other PPE appropri-
ate for this task (293). Category IC (OSHA: 29
CFR 1910.1030 § d.3.i, ii)
 2. If the spill contains large amounts of blood or
body fluids, clean the visible matter with dis-
posable absorbent material, and discard the used
cleaning materials in appropriate, labeled con-
tainers (293,298,299,301,302). Category IC
(OSHA: 29 CFR 1910.1030 § d.4.iii.B)
3. Swab the area with a cloth or paper towels mod-
erately wetted with disinfectant, and allow the
surface to dry (293,301). Category IC (OSHA:
29 CFR 1910.1030 § d.4.ii.A)
C. Use germicides registered by the EPA for use as hos-
pital disinfectants and labeled tuberculocidal or reg-
istered germicides on the EPA Lists D and E (i.e.,
products with specific label claims for HIV or hepa-
titis B virus [HBV]) in accordance with label
instructions to decontaminate spills of blood and
other body fluids (293,301,303). Category IC
(OSHA 29 CFR 1910.1030 § d.4.ii. A memoran-
dum 2/28/97; compliance document [CPL]
2-2.44D [11/99])
D. An EPA-registered sodium hypochlorite product is
preferred, but if such products are not available,
generic sodium hypochlorite solutions (e.g., house-
hold chlorine bleach) may be used.
1. Use a 1:100 dilution (500–615 ppm available
chlorine) to decontaminate nonporous surfaces
after cleaning a spill of either blood or body fluids
in patient-care settings (301,304). Category IB
2. If a spill involves large amounts of blood or body
fluids, or if a blood or culture spill occurs in the
laboratory, use a 1:10 dilution (5,000–6,150
ppm available chlorine) for the first application
of germicide before cleaning (279,301). Cat-
egory IB
III. Carpeting and Cloth Furnishings
A. Vacuum carpeting in public areas of health-care
facilities and in general patient-care areas regularly
with well-maintained equipment designed to mini-
mize dust dispersion (280). Category II
B. Periodically perform a thorough, deep cleaning of
carpeting as determined by facility policy by using a
method that minimizes the production of aerosols
and leaves little or no residue (44). Category II
C. Avoid use of carpeting in high-traffic zones in
patient-care areas or where spills are likely (e.g., burn
therapy units, operating rooms, laboratories, or
intensive care units) (44,305,306). Category IB
D. Follow appropriate procedures for managing spills
on carpeting.
1. Spot-clean blood or body substance spills
promptly (293,301,304,307). Category IC
(OSHA: 29 CFR 1910.1030 § d.4.ii.A, inter-
pretation)
2. If a spill occurs on carpet tiles, replace any tiles
contaminated by blood and body fluids or body
substances (307). Category IC (OSHA 29 CFR
1910.1030 § d.4.ii interpretation)
E. Thoroughly dry wet carpeting to prevent the growth
of fungi; replace carpeting that remains wet after 72
hours (37,160). Category IB
F. No recommendation is offered regarding the rou-
tine use of fungicidal or bactericidal treatments for
carpeting in public areas of a health-care facility or
in general patient-care areas. Unresolved issue
G. Do not use carpeting in hallways and patient rooms
in areas housing immunosuppressed patients (e.g.,
PE areas) (37,44). Category IB
H. Avoid using upholstered furniture and furnishings
in high-risk patient-care areas and in areas with
increased potential for body substance contamina-
tion (e.g., pediatrics units) (37). Category II
I. No recommendation is offered regarding whether
upholstered furniture and furnishings should be
avoided in general patient-care areas. Unresolved
issue
1. Maintain upholstered furniture in good repair.
Category II
2. Maintain the surface integrity of the upholstery
by repairing tears and holes. Category II
3. If upholstered furniture in a patient’s room
requires cleaning to remove visible soil or body
substance contamination, move that item to a
maintenance area where it can be adequately
cleaned with a process appropriate for the type
of upholstery and nature of the soil. Category II
IV. Flowers and Plants in Patient-Care Areas
A. Flowers and potted plants need not be restricted from
areas for immunocompetent patients (308–311).
Category II
B. Designate care and maintenance of flowers and pot-
ted plants to staff not directly involved with patient
care (309). Category II
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C. If plant or flower care by patient-care staff is
unavoidable, instruct the staff to wear gloves when
handling plants and flowers and perform hand
hygiene after glove removal (309). Category II
D. Do not allow fresh or dried flowers, or potted plants,
in patient-care areas for immunosuppressed patients
(37,51,308,312). Category II
V. Pest Control
A. Develop pest-control strategies, with emphasis on
kitchens, cafeterias, laundries, central sterile supply
areas, operating rooms, loading docks, construction
activities, and other areas prone to infestations (313–
315). Category II
B. Install screens on all windows that open to the out-
side; keep screens in good repair (314). Category IB
C. Contract for routine pest control service by a cre-
dentialed pest-control specialist who will tailor the
application to the needs of a health-care facility
(315). Category II
D. Place laboratory specimens (e.g., fixed sputum
smears) in covered containers for overnight storage
(316,317). Category II
VI. Special Pathogens
A. Use appropriate hand hygiene, PPE (e.g., gloves),
and isolation precautions during cleaning and disin-
fecting procedures (146,274,318,319). Category IB
B. Use standard cleaning and disinfection protocols to
control environmental contamination with antibi-
otic-resistant, gram-positive cocci (e.g., methicillin-
resistant Staphylococcus aureus, vancomycin
intermediate sensitive Staphylococcus aureus, or van-
comycin-resistant Enterococcus [VRE]) (318,320–
322). Category IB
1. Pay close attention to cleaning and disinfection
of high-touch surfaces in patient-care areas (e.g.,
bed rails, carts, charts, bedside commodes, bed
rails, doorknobs, or faucet handles) (318,320–
322). Category IB
2. Ensure compliance by housekeeping staff with
cleaning and disinfection procedures (318,320–
322). Category IB
3. Use EPA-registered chemical germicides appro-
priate for the surface to be disinfected (e.g.,
either low- or intermediate-level disinfection) as
specified by the manufacturer’s instructions
(271,322–327). Category IB, IC (EPA: 7 USC
§ 136 et seq.)
4. When contact precautions are indicated for
patient care, use disposable patient-care items
(e.g., blood pressure cuffs) wherever possible to
minimize cross-contamination with multiple-
resistant microorganisms (328). Category IB
5. Follow these same surface-cleaning and disin-
fecting measures for managing the environment
of VRSA patients (320–322,327). Category II
C. Environmental-surface culturing can be used to
verify the efficacy of hospital policies and procedures
before and after cleaning and disinfecting rooms that
house patients with VRE (318,329–333). Category II
1. Obtain prior approval from infection-control staff
and the clinical laboratory before performing
environmental-surface culturing. Category II
2. Infection-control staff, with clinical laboratory
staff consultation, must supervise all environ-
mental culturing. Category II
D. Thoroughly clean and disinfect environmental and
medical equipment surfaces on a regular basis by
using EPA-registered disinfectants in accordance
with manufacturers’ instructions (271,274,319,
334). Category IB, IC (EPA: 7 USC § 136 et seq.)
E. Advise families, visitors, and patients regarding the
importance of hand hygiene to minimize the spread
of body substance contamination (e.g., respiratory
secretions or fecal matter) to surfaces (274). Cat-
egory II
F. Do not use high-level disinfectants (i.e., liquid
chemical sterilants) on environmental surfaces; such
use is inconsistent with label instructions because
of the toxicity of the chemicals (270,273,274,278).
Category IC (FDA: 21 CFR 801.5, 807.87.e)
G. Because no EPA-registered products are specific for
inactivating Clostridium difficile spores, use
hypochlorite-based products for disinfection of
environmental surfaces in accordance with guidance
from the scientific literature in those patient-care
areas where surveillance and epidemiology indicate
ongoing transmission of C. difficile (274,319,334).
Category II
H. No recommendation is offered regarding the use of
specific EPA-registered hospital disinfectants with
respect to environmental control of C. difficile.
Unresolved issue
I. Apply standard cleaning and disinfection procedures
to control environmental contamination with res-
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piratory and enteric viruses in pediatric-care units
and care areas for immunocompromised patients
(280,335). Category IC (EPA: 7 USC § 136 et seq.)
J. Clean surfaces that have been contaminated with
body substances; perform low- to intermediate-level
disinfection on cleaned surfaces with an EPA-
registered disinfectant in accordance with the
manufacturer’s instructions (271,293,335). Cat-
egory IC (OSHA: 29 CFR 1910.1030 § d.4.ii.A;
EPA: 7 USC § 136 et seq.)
K. Use disposable barrier coverings as appropriate to
minimize surface contamination. Category II
L. Develop and maintain cleaning and disinfection
procedures in patient-care areas to control environ-
mental contamination with agents of Creutzfeldt-
Jakob disease (CJD), for which no EPA-registered
product exists. Category II
1. In the absence of contamination with central
nervous system tissue, extraordinary measures
(e.g., use of 2N sodium hydroxide [NaOH] or
applying full-strength sodium hypochlorite) are
not needed for routine cleaning or terminal dis-
infection of a room housing a confirmed or sus-
pected CJD patient (273,336). Category II
2. After removing gross tissue from the surface, use
either 1N NaOH or a sodium hypochlorite
solution containing approximately 10,000–
20,000 ppm available chlorine (dilutions of 1:5
to 1:3 v/v, respectively, of U.S. household chlo-
rine bleach; contact the manufacturers of com-
mercially available sodium hypochlorite
products for advice) to decontaminate operat-
ing room or autopsy surfaces with central ner-
vous system or cerebral spinal fluid
contamination from a diagnosed or suspected
CJD patient (273,337–342). Category II
a. The contact time for the chemical used dur-
ing this process should be 30 min–1 hour
(339,340,342).
b. Blot up the chemical with absorbent mate-
rial and rinse the treated surface thoroughly
with water.
c. Discard the used, absorbent material into
appropriate waste containers.
3. Use disposable, impervious covers to minimize
body substance contamination to autopsy tables
and surfaces (340,342). Category II
M. Use standard procedures for containment, cleaning,
and decontamination of blood spills on surfaces as
previously described (Environmental Services: II)
(293). Category IC (OSHA: 29 CFR 1910.1030 §
d.4.ii.A)
1. Wear PPE appropriate for a surface decontami-
nation and cleaning task (293,336). Category
IC (OSHA 29 CFR 1910.1030 § d.3.i, ii)
2. Discard used PPE by using routine disposal pro-
cedures or decontaminate reusable PPE as
appropriate (293,336). Category IC (OSHA 29
CFR 1910.1030 § d.3.viii)
Recommendations —
Environmental Sampling
I. General Information
A. Do not conduct random, undirected, microbiologic
sampling of air, water, and environmental surfaces
in health-care facilities (270,343). Category IB
B. When indicated, conduct microbiologic sampling
as part of an epidemiologic investigation or during
assessment of hazardous environmental conditions
to detect contamination or verify abatement of a
hazard (270,343). Category IB
C. Limit microbiologic sampling for quality assurance
purposes to 1) biologic monitoring of sterilization
processes; 2) monthly cultures of water and dialy-
sate in hemodialysis units; and 3) short-term evalu-
ation of the impact of infection-control measures
or changes in infection-control protocols (270,343).
Category IB
II. Air, Water, and Environmental Surface Sampling
A. When conducting any form of environmental sam-
pling, identify existing comparative standards and
fully document departures from standard methods
(343–347). Category II
B. Select a high-volume air sampling device if antici-
pated levels of microbial airborne contamination are
expected to be low (345,346,348,349). Category II
C. Do not use settle plates to quantify the concentra-
tion of airborne fungal spores (348). Category II
D. When sampling water, choose growth media and
incubation conditions that will facilitate recovery
of waterborne organisms (344). Category II
E. When using a sample/rinse method for sampling
an environmental surface, develop and document a
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procedure for manipulating the swab, gauze, or
sponge in a reproducible manner so that results are
comparable (347). Category II
F. When environmental samples and patient specimens
are available for comparison, perform the labora-
tory analysis on the recovered microorganisms down
to the species level at a minimum, and beyond the
species level if possible (343). Category II
Recommendations —
Laundry and Bedding
I. Employer Responsibilities
A. Employers must launder workers’ personal protec-
tive garments or uniforms that are contaminated
with blood or other potentially infectious materials
(293). Category IC (OSHA: 29 CFR 1910.1030 §
d.3.iv)
II. Laundry Facilities and Equipment
A. Maintain the receiving area for contaminated tex-
tiles at negative pressure compared with the clean
areas of the laundry in accordance with AIA con-
struction standards in effect during the time of
facility construction (1,350–352). Category IC
(AIA: 7.23.B1, B2)
B. Ensure that laundry areas have handwashing facili-
ties and products and appropriate PPE available for
workers (1,293). Category IC (AIA: 7.23.D4;
OSHA: 29 CFR 1910.1030 § d.2.iii)
C. Use and maintain laundry equipment according to
manufacturers’ instructions (353,354). Category II
D. Do not leave damp textiles or fabrics in machines
overnight (353). Category II
E. Disinfection of washing and drying machines in
residential care is not needed as long as gross soil is
removed from items before washing and proper wash-
ing and drying procedures are used. Category II
III. Routine Handling of Contaminated Laundry
A. Handle contaminated textiles and fabrics with mini-
mum agitation to avoid contamination of air, sur-
faces, and persons (36,293,355,356). Category IC
(OSHA: 29 CFR 1910.1030 § d.4.iv)
B. Bag or otherwise contain contaminated textiles and
fabrics at the point of use (293). Category IC
(OSHA: 29 CFR 1910.1030 § d.4.iv)
1. Do not sort or prerinse contaminated textiles or
fabrics in patient-care areas (293). Category IC
(OSHA: 29 CFR 1910.1030 § d.4.iv)
2. Use leak-resistant containment for textiles and
fabrics contaminated with blood or body sub-
stances (293,355). Category IC (OSHA: 29
CFR 1910.1030 § d.4.iv)
3. Identify bags or containers for contaminated
textiles with labels, color coding, or other alter-
native means of communication as appropriate
(293). Category IC (OSHA: 29 CFR 1910.1030
§ d.4.iv)
C. Covers are not needed on contaminated textile ham-
pers in patient-care areas. Category II
D. If laundry chutes are used, ensure that they are prop-
erly designed, maintained, and used in a manner to
minimize dispersion of aerosols from contaminated
laundry (357–361). Category IC (AAMI: ANSI/
AAMI ST65:2000)
1. Ensure that laundry bags are closed before toss-
ing the filled bag into the chute. Category II
2. Do not place loose items in the laundry chute.
Category II
E. Establish a facility policy to determine when textiles
or fabrics should be sorted in the laundry facility (i.e.,
before or after washing) (362,363). Category II
IV. Laundry Process
A. If hot-water laundry cycles are used, wash with
detergent in water >160ºF (>71ºC) for >25 minutes
(1,270). Category IC (AIA: 7.31.E3)
B. No recommendation is offered regarding a hot-
water temperature setting and cycle duration for
items laundered in residence-style health-care facili-
ties. Unresolved issue
C. Follow fabric-care instructions and special launder-
ing requirements for items used in the facility (364).
Category II
D. Choose chemicals suitable for low-temperature
washing at proper use concentration if low-
temperature (<160ºF [<70ºC ]) laundry cycles are
used (365–370). Category II
E. Package, transport, and store clean textiles and fab-
rics by methods that will ensure their cleanliness and
protect them from dust and soil during interfacility
loading, transport, and unloading (270). Category II
V. Microbiologic Sampling of Textiles
A. Do not conduct routine microbiologic sampling of
clean textiles (270,371). Category IB
B. Use microbiologic sampling during outbreak inves-
tigations if epidemiologic evidence indicates a role
for health-care textiles and clothing in disease trans-
mission (371). Category IB
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VI. Special Laundry Situations
A. Use sterilized textiles, surgical drapes, and gowns
for situations requiring sterility in patient care (114).
Category IB
B. Use hygienically clean textiles (i.e., laundered, but
not sterilized) in neonatal intensive care units
(292,372). Category IB
C. Follow manufacturers’ recommendations for clean-
ing fabric products, including those with coated or
laminated surfaces. Category II
D. Do not use dry cleaning for routine laundering in
health-care facilities (373–375). Category II
E. Use caution when considering use of antimicrobial
mattresses, textiles, and clothing as replacements for
standard bedding and other fabric items; EPA has
not approved public health claims asserting protec-
tion against human pathogens for such treated items
(376). Category II
F. No recommendation is offered regarding using dis-
posable fabrics and textiles versus durable goods.
Unresolved issue
VII. Mattresses and Pillows
A. Keep mattresses dry; discard them if they remain
wet or stained, particularly in burn units (377–382).
Category IB
B. Clean and disinfect mattress covers by using EPA-
registered disinfectants that are compatible with the
materials to prevent the development of tears, cracks,
or holes in the covers (377–382). Category IB
C. Maintain the integrity of mattress and pillow cov-
ers. Category II
1. Replace mattress and pillow covers if they
become torn or otherwise in need of repair. Cat-
egory II
2. Do not stick needles into a mattress through the
cover. Category II
D. Clean and disinfect moisture-resistant mattress cov-
ers between patient use by using an EPA-registered
product (377–382). Category IB
E. If using a mattress cover completely made of fabric,
change these covers and launder between patient use
(377–382). Category IB
F. Launder pillow covers and washable pillows in the
hot-water cycle between patients or when they
become contaminated with body substances (382).
Category IB
VIII. Air-Fluidized Beds
A. Follow manufacturers’ instructions for air-fluidized bed
maintenance and decontamination. Category II
B. Change the polyester filter sheet at least weekly or
as indicated by the manufacturer (383–386). Cat-
egory II
C. Clean and disinfect the polyester filter sheet thor-
oughly, especially between patients, using an EPA-
registered product (383–386). Category IB
D. Consult the facility engineer to determine the proper
placement of air-fluidized beds in negative-pressure
rooms (387). Category II
Recommendations — Animals
in Health-Care Facilities
I. General Infection-Control Measures for Animal En-
counters
A. Minimize contact with animal saliva, dander, urine,
and feces (388–390). Category II
B. Practice hand hygiene after any animal contact
(146,270). Category II
1. Wash hands with soap and water, especially if
hands are visibly soiled or contaminated with
proteinaceous material (146). Category II
2. Use either soap and water or alcohol-based hand
rubs when hands are not visibly soiled or con-
taminated (146). Category II
II. Animal-Assisted Activities and Resident Animal
Programs
A. Avoid selection of nonhuman primates and reptiles
in animal-assisted activities, animal-assisted therapy,
or resident animal programs (391–393). Category IB
B. Enroll animals that are fully vaccinated for zoonotic
diseases and that are healthy, clean, well-groomed,
and negative for enteric parasites or otherwise have
completed recent anthelmintic treatment under the
regular care of a veterinarian (391,394). Category II
C. Enroll animals that are trained with the assistance
or under the direction of persons who are experi-
enced in this field (391). Category II
D. Ensure that animals are controlled by persons trained
in providing activities or therapies safely, and who
know the animal’s health status and behavior traits
(391,394). Category II
E. Take prompt action when an incident of biting or
scratching by an animal occurs during an animal-
assisted activity or therapy.
1. Remove the animal permanently from these pro-
grams (391). Category II
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2. Report the incident promptly to appropriate
authorities (e.g., infection-control staff, animal
program coordinator, or local animal control
personnel) (391). Category II
3. Promptly clean and treat scratches, bites, or other
breaks in the skin. Category II
F. Perform an ICRA and work actively with the ani-
mal handler before conducting an animal-assisted
activity or therapy to determine whether the session
should be held in a public area of the facility or in
individual patient rooms (391,394). Category II
G. Take precautions to mitigate allergic responses to
animals. Category II
1. Minimize shedding of animal dander by bath-
ing animals <24 hours before a visit (391). Cat-
egory II
2. Groom animals to remove loose hair before a
visit, or use a therapy animal cape (395). Cat-
egory II
H. Use routine cleaning protocols for housekeeping
surfaces after therapy sessions. Category II
I. Restrict resident animals, including fish in tanks,
from access to patient-care areas, food-preparation
areas, dining areas, laundry, central sterile supply
areas, sterile and clean supply storage areas, medica-
tion preparation areas, operating rooms, isolation
areas, and PE areas. Category II
J. Establish a facility policy for regular cleaning of fish
tanks, rodent cages, and bird cages, and any other
animal dwellings and assign this cleaning task to a
nonpatient-care staff member; avoid splashing tank
water or contaminating environmental surfaces with
animal bedding. Category II
III. Protective Measures for Immunocompromised
Patients
A. Advise patients to avoid contact with animal feces,
saliva, urine, or solid litter box material (396). Cat-
egory II
B. Promptly clean and treat scratches, bites, or other
wounds that break the skin (396). Category II
C. Advise patients to avoid direct or indirect contact
with reptiles (397). Category IB
D. Conduct a case-by-case assessment to determine if
animal-assisted activities or animal-assisted therapy
programs are appropriate for immunocompromised
patients (394). Category II
E. No recommendation is offered regarding permit-
ting pet visits to terminally ill immunocompromised
patients outside their PE units. Unresolved issue.
IV. Service Animals
A. Avoid providing facility access to nonhuman pri-
mates and reptiles as service animals (393,397).
Category IB
B. Allow service animals access to the facility in accor-
dance with the Americans with Disabilities Act of
1990, unless the presence of the animal creates a
direct threat to other persons or a fundamental
alteration in the nature of services (389,398). Cat-
egory IC (U.S. Department of Justice: 28 CFR §
36.302)
C. When a decision must be made regarding a service
animal’s access to any particular area of the health-
care facility, evaluate the service animal, patient, and
health-care situation on a case-by-case basis to
determine whether significant risk of harm exists
and whether reasonable modifications in policies and
procedures will mitigate this risk (398). Category
IC (U.S. Department of Justice: 28 CFR § 36.208)
D. If a patient must be separated from his or her ser-
vice animal while in the health-care facility 1)
ascertain from the person what arrangements have
been made for supervision or care of the animal
during this period of separation; and 2) make appro-
priate arrangements to address the patient’s needs in
the absence of the service animal. Category II
V. Animals as Patients in Human Health-Care
Facilities
A. Develop health-care facility policies to address the
treatment of animals in human health-care facili-
ties.
1. Use the multidisciplinary team approach to
policy development, including public media
relations efforts to disclose and discuss these
activities. Category II
2. Exhaust all veterinary facility, equipment, and
instrument options before undertaking the pro-
cedure. Category II
3. Ensure that the care of the animal is supervised
by a licensed veterinarian. Category II
B. When animals are treated in human health-care
facilities, avoid treating animals in operating rooms
or other patient-care areas where invasive procedures
are performed (e.g., cardiac catheterization laborato-
ries or invasive nuclear medicine areas). Category II
C. Schedule the animal procedure for the last proce-
dure of the day in the area, at a time when human
patients are not scheduled to be in the vicinity. Cat-
egory II
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D. Adhere strictly to standard precautions. Category II
E. Clean and disinfect environmental surfaces thor-
oughly by using an EPA-registered product in the
room after the animal has been removed. Category II
F. Allow sufficient ACH to clean the air and help
remove airborne dander, microorganisms, and
allergens (Table 1). Category II
G. Clean and disinfect using EPA-registered products
or sterilize equipment that has been in contact with
the animal; or use disposable equipment. Category II
H. If reusable medical or surgical instruments are used
in an animal procedure, restrict future use of these
instruments to animals only. Category II
VI. Research Animals in Health-Care Facilities
A. Use animals obtained from quality stock, or quar-
antine incoming animals to detect zoonotic diseases.
Category II
B. Treat sick animals or remove them from the facility.
Category II
C. Provide prophylactic vaccinations, as available, to
animal handlers and contacts at high risk. Category II
D. Ensure proper ventilation through appropriate
facility design and location (399). Category IC (U.S.
Department of Agriculture [USDA]: 7 USC 2131)
1. Keep animal rooms at negative pressure relative
to corridors (399). Category IC (USDA: 7 USC
2131)
2. Prevent air in animal rooms from recirculating
elsewhere in the health-care facility (399). Cat-
egory IC (USDA: 7 USC 2131)
E. Keep doors to animal research rooms closed. Cat-
egory II
F. Restrict access to animal facilities to essential per-
sonnel. Category II
G. Establish employee occupational health programs
specific to the animal research facility, and coordi-
nate management of postexposure procedures spe-
cific to zoonoses with occupational health clinics in
the health-care facility (400,401). Category IC (U.S.
Department of Health and Human Services
[DHHS]: Biosafety in Microbiological and Bio-
medical Laboratories [BMBL]; OSHA: 29 CFR
1910.1030.132-139)
H. Document standard operating procedures for the
unit (400). Category IC (DHHS: BMBL)
I. Conduct routine employee training on worker safety
concerns relevant to the animal research facility (e.g.,
working safely with animals, animal handling)
(400,401). Category IC (DHHS: BMBL; OSHA:
29 CFR 1910.1030.132–139)
J. Use precautions to prevent development of animal-
induced asthma in animal workers (400). Category
IC (DHHS: BMBL)
Recommendations — Regulated
Medical Wastes
I. Categories of Regulated Medical Waste
A. Designate the following as major categories of medi-
cal waste that require special handling and disposal
precautions: 1) microbiology laboratory wastes [e.g.,
cultures and stocks of microorganisms]; 2) bulk
blood, blood products, blood, and bloody body fluid
specimens; 3) pathology and anatomy waste; and 4)
sharps [e.g., needles and scalpels] (270). Category II
B. Consult federal, state, and local regulations to
determine if other waste items are considered regu-
lated medical wastes (293,402,403). Category IC
(States; OSHA: 29 CFR 1910.1030 § g.2.1;
Department of Transportation [DOT]: 49 CFR
171-180; U.S. Postal Service: CO23.8)
II. Disposal Plan for Regulated Medical Wastes
A. Develop a plan for the collection, handling,
predisposal treatment, and terminal disposal of regu-
lated medical wastes (293,404). Category IC (States;
OSHA: 29 CFR 1910.1030 § g.2.i)
B. Designate a person or persons as responsible for
establishing, monitoring, reviewing, and adminis-
tering the plan. Category II
III. Handling, Transporting, and Storing Regulated
Medical Wastes
A. Inform personnel involved in handling and disposal
of potentially infective waste of possible health and
safety hazards; ensure that they are trained in
appropriate handling and disposal methods (293).
Category IC (OSHA: 29 CFR 1910.1030 § g.2.i)
B. Manage the handling and disposal of regulated medi-
cal wastes generated in isolation areas by using the
same methods used for regulated medical wastes
from other patient-care areas (270). Category II
C. Use proper sharps disposal strategies (293). Category
IC (OSHA: 29 CFR 1910.1030 § d.4.iii.A)
1. Use a sharps container capable of maintaining
its impermeability after waste treatment to avoid
subsequent physical injuries during final disposal
(293). Category IC (OSHA: 29 CFR 1910.1030
§ d.4.iii.A)
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2. Place disposable syringes with needles, includ-
ing sterile sharps that are being discarded, scal-
pel blades, and other sharp items into
puncture-resistant containers located as close as
practical to the point of use (293). Category IC
(OSHA: 29 CFR 1910.1030 § d.4.iii.A)
3. Do not bend, recap, or break used syringe needles
before discarding them into a container
(36,293,405). Category IC (OSHA: 29 CFR
1910.1030 § d.2.vii and § d.2.vii.A)
D. Store regulated medical wastes awaiting treatment
in a properly ventilated area inaccessible to verte-
brate pests; use waste containers that prevent devel-
opment of noxious odors. Category IC (States)
E. If treatment options are not available at the site where
the medical waste is generated, transport regulated
medical wastes in closed, impervious containers to
the on-site treatment location or to another facility
for treatment as appropriate. Category IC (States)
IV. Treatment and Disposal of Regulated Medical Wastes
A. Treat regulated medical wastes by using a method
(e.g., steam sterilization, incineration, interment, or
an alternative treatment technology) approved by
the appropriate authority having jurisdiction (AHJ)
(e.g., state, Indian Health Service, or Veterans
Administration) before disposal in a sanitary land-
fill. Category IC (States, AHJ)
B. Follow precautions for treating microbiologic wastes
(e.g., amplified cultures and stocks of microorgan-
isms) (400). Category IC (DHHS: BMBL)
1. Biosafety level 4 laboratories must inactivate
microbiologic wastes in the laboratory by using
an approved inactivation method (e.g., autoclav-
ing) before transport to and disposal in a sani-
tary landfill (400). Category IC (DHHS:
BMBL)
2. Biosafety level 3 laboratories must inactivate
microbiologic wastes in the laboratory by using
an approved inactivation method (e.g., autoclav-
ing) or incinerate them at the facility before
transport to and disposal in a sanitary landfill
(400). Category IC (DHHS: BMBL)
C. Biosafety levels 1 and 2 laboratories should develop
strategies to inactivate amplified microbial cultures
and stocks onsite by using an approved inactivation
method (e.g., autoclaving) instead of packaging and
shipping untreated wastes to an offsite facility for
treatment and disposal (400,406–408). Category II
D. Laboratories that isolate select agents from clinical
specimens must comply with federal regulations for
receipt, transfer, management, and appropriate dis-
posal of these agents (409). Category IC (DHHS:
42 CFR 72 § 72.6.i.1.iii)
E. Sanitary sewers may be used for safe disposal of
blood, suctioned fluids, ground tissues, excretions,
and secretions, provided that local sewage discharge
requirements are met and that the state has declared
this to be an acceptable method of disposal (410).
Category II
V. Special Precautions for Wastes Generated During
Care of Patients with Rare Diseases
A. When discarding items contaminated with blood
and body fluids from VHF patients, contain these
regulated medical wastes with minimal agitation
during handling (36,109). Category II
B. Manage properly contained wastes from areas pro-
viding care to VHF patients in accordance with rec-
ommendations for other isolation areas (Regulated
Medical Waste: III B) (36,109,270). Category II
C. Decontaminate bulk blood and body fluids from
VHF patients by using approved inactivation meth-
ods (e.g., autoclaving or chemical treatment) before
disposal (36,109). Category IC, II (States)
D. When discarding regulated medical waste generated
during the routine (i.e., nonsurgical) care of CJD
patients, contain these wastes and decontaminate
them by using approved inactivation methods (e.g.,
autoclaving or incineration) appropriate for the
medical waste category (e.g., blood, sharps, or patho-
logical waste) (36,270,273,336). Category IC, II
(States)
E. Incinerate medical wastes (e.g., central nervous sys-
tem tissues or contaminated disposable materials)
from brain autopsy or biopsy procedures of diag-
nosed or suspected CJD patients (340,342). Cat-
egory IB
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Appendix
Water Sampling Strategies and Culture Techniques for Detecting Legionellae
Water samples and swabs from point-of-use devices or sys-
tem surfaces should be collected when sampling for legionellae
(Box 1, Box 2 in text) (9). Swabs of system surfaces allow
sampling of biofilms, which frequently contain legionellae.
When culturing faucet aerators and shower heads, swabs of
surface areas should be collected first; water samples are col-
lected after aerators or shower heads are removed from their
pipes. Swabs can be streaked directly onto buffered charcoal
yeast extract agar plates if the plates are available at the collec-
tion site. If the swabs and water samples must be transported
back to a laboratory for processing, immersing individual swabs
in sample water minimizes drying during transit. Place swabs
and water samples in insulated coolers to protect specimens
from temperature extremes.
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Legionella spp. are ubiquitous and can be isolated from 20%–
40% of freshwater environments, including man-made water
systems (1,2). In health-care facilities, where legionellae in
potable water rarely result in disease among nonimmuno-
compromised patients, courses of remedial action are unclear.
Scheduled microbiologic monitoring for legionellae remains
controversial because the presence of legionellae is not neces-
sarily evidence of a potential for causing disease (3). CDC
recommends aggressive disinfection measures for cleaning and
maintaining devices known to transmit legionellae, but does
not recommend regularly scheduled microbiologic assays for
the bacteria (4). However, scheduled monitoring of potable
water within a hospital might be considered in certain settings
where persons are highly susceptible to illness and mortality
from Legionella infection (e.g., hematopoietic stem cell trans-
plantation units and solid organ transplant units) (5). Also,
after an outbreak of legionellosis, health officials agree moni-
toring is necessary to identify the source and to evaluate the
efficacy of biocides or other prevention measures.
Examination of water samples is the most efficient micro-
biologic method for identifying sources of legionellae and is
an integral part of an epidemiologic investigation into health-
care–associated Legionnaires’ disease. Because of the diversity
of plumbing and HVAC systems in health-care facilities, the
number and types of sites to be tested must be determined
before collection of water samples. One environmental sam-
pling protocol that addresses sampling site selection in hospi-
tals might serve as a prototype for sampling in other institutions
(6). Any water source that might be aerosolized should be con-
sidered a potential source for transmission of legionellae. The
bacteria are rarely found in municipal water supplies and tend
to colonize plumbing systems and point-of-use devices. To
colonize, legionellae usually require a temperature range of
77ºF–108ºF (25ºC–42.2ºC ) (7) and are most commonly
located in hot water systems. Legionellae do not survive dry-
ing. Therefore, air-conditioning equipment condensate, which
frequently evaporates, is not a likely source (8).
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This report summarizes West Nile virus (WNV) surveillance
data reported to CDC through ArboNET and by states and
other jurisdictions as of August 7, 2002.
United StatesDuring the reporting period of July 31–August 7, a total of
68 laboratory-positive human cases of WNV-associated ill-
ness were reported from Louisiana (n=40), Mississippi (n=23),
Texas (n=four), and Illinois (n=one). During the same
period, WNV infections were reported in 447 dead crows,
263 other dead birds, 42 horses, and 183 mosquito pools.
During 2002, a total of 112 human cases with laboratory
evidence of recent WNV infection have been reported from
Louisiana (n=71), Mississippi (n=28), Texas (n=12), and Illi-
nois (n=one). Five deaths have been reported, all from Louisi-
ana. Among the 98 cases with available data, 59 (60%)
occurred among men; the median age was 55 years (range:
3–88 years), and the dates of illness onset ranged from June 10
to July 29.In addition, 1,076 dead crows and 827 other dead birds
with WNV infection were reported from 34 states, New York
City, and the District of Columbia (Figure 1); 87 WNV
infections in horses have been reported from 12 states
(Alabama, Florida, Georgia, Illinois, Kentucky, Louisiana,
Minnesota, Mississippi, North Dakota, South Dakota, Ten-
nessee, and Texas). During 2002, WNV seroconversions have
been reported in 52 sentinel chicken flocks from Florida,
Nebraska, and Pennsylvania; and 425 WNV-positive mos-
quito pools have been reported from 12 states (Alabama, Geor-
gia, Illinois, Indiana, Massachusetts, Mississippi, New Jersey,
Ohio, Pennsylvania, South Dakota, Texas, and Virginia), New
York City, and the District of Columbia.
West Nile Virus Activity — United States, July 31–August 7, 2002,
and Louisiana, January 1–August 7, 2002
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